<!DOCTYPE html><html lang="en"><head><title>Static News</title><meta charSet="utf-8"/><meta name="description" content="Static delayed Hacker News."/><meta name="theme-color" media="(prefers-color-scheme: light)" content="white"/><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1d1f21"/><meta name="viewport" content="width=device-width,initial-scale=1.0"/><meta name="application-name" content="Static News"/><meta name="apple-mobile-web-app-title" content="Static News"/><meta name="apple-mobile-web-app-capable" content="yes"/><meta name="mobile-web-app-capable" content="yes"/><meta name="apple-mobile-web-app-status-bar-style" content="#1d1f21"/><link rel="preload" href="styles.css?v=1723107666744" as="style"/><link rel="stylesheet" href="styles.css?v=1723107666744"/></head><body><div id="container"><div id="inner"><header><a href="/">Static News</a><a href="/about">about</a></header><div id="content"><div><div id="title"><a href="https://www.science.org/content/blog-post/prevention-hiv">Prevention of HIV</a>Â <span class="domain">(<a href="https://www.science.org">www.science.org</a>)</span></div><div class="subtext"><span>etiam</span> | <span>212 comments</span></div><br/><div><div id="41185700" class="c"><input type="checkbox" id="c-41185700" checked=""/><div class="controls bullet"><span class="by">inasio</span><span>|</span><a href="#41185536">next</a><span>|</span><label class="collapse" for="c-41185700">[-]</label><label class="expand" for="c-41185700">[21 more]</label></div><br/><div class="children"><div class="content">One other very cool thing here is that this new treatment represents a whole new family of drugs (very sophisticated at that, per Derek Lowe&#x27;s assessment). I thought back in the late 2010s with integrase inhibitors (e.g. dolutegravir), there was a real chance they could achieve the 90-95% reduction targets in new cases, and hopefully this new drug makes that even more feasible.<p>There&#x27;s always the risk of losing previously effective drugs due to resistance, so the value of redundancy cannot be overstated</div><br/><div id="41185777" class="c"><input type="checkbox" id="c-41185777" checked=""/><div class="controls bullet"><span class="by">w10-1</span><span>|</span><a href="#41185700">parent</a><span>|</span><a href="#41187672">next</a><span>|</span><label class="collapse" for="c-41185777">[-]</label><label class="expand" for="c-41185777">[17 more]</label></div><br/><div class="children"><div class="content">Here&#x27;s a summary including the mechanism of action from a UW professor in 2022:<p><a href="https:&#x2F;&#x2F;www.youtube.com&#x2F;watch?v=9IbzMbfEMIY" rel="nofollow">https:&#x2F;&#x2F;www.youtube.com&#x2F;watch?v=9IbzMbfEMIY</a></div><br/><div id="41186163" class="c"><input type="checkbox" id="c-41186163" checked=""/><div class="controls bullet"><span class="by">hilbert42</span><span>|</span><a href="#41185700">root</a><span>|</span><a href="#41185777">parent</a><span>|</span><a href="#41186842">next</a><span>|</span><label class="collapse" for="c-41186163">[-]</label><label class="expand" for="c-41186163">[12 more]</label></div><br/><div class="children"><div class="content">Not my field so please bear with me. Before watching the video 
the notion of interfering with the capsid as a mechanism for stopping the virus made sense.<p>However, what I still don&#x27;t have a handle on is how does lenacapavir act so long that it only needs to be administered every six months?<p>From the explanation lenacapavir works on the capsid directly, it&#x27;s not acting on the immune system by training the body&#x27;s defences as with a traditional vaccine. Surely this molecule can&#x27;t just hang around for six months without being gobbled up by the liver or such.<p>What am I missing here?</div><br/><div id="41186226" class="c"><input type="checkbox" id="c-41186226" checked=""/><div class="controls bullet"><span class="by">jaggederest</span><span>|</span><a href="#41185700">root</a><span>|</span><a href="#41186163">parent</a><span>|</span><a href="#41187865">next</a><span>|</span><label class="collapse" for="c-41186226">[-]</label><label class="expand" for="c-41186226">[2 more]</label></div><br/><div class="children"><div class="content">It&#x27;s got so many fluorines running around that intuitively as an amateur chemist I would expect it to have an extraordinarily long half life in the human body, especially so if it&#x27;s administered as a depot injection in something with a large molecular weight. It takes your body a long time to chew through the inactive components in a depot injection.</div><br/><div id="41186277" class="c"><input type="checkbox" id="c-41186277" checked=""/><div class="controls bullet"><span class="by">hilbert42</span><span>|</span><a href="#41185700">root</a><span>|</span><a href="#41186226">parent</a><span>|</span><a href="#41187865">next</a><span>|</span><label class="collapse" for="c-41186277">[-]</label><label class="expand" for="c-41186277">[1 more]</label></div><br/><div class="children"><div class="content">Yeah, I also noted the fluorines (and Lowe&#x27;s comment), and I know they&#x27;re used to prolong action such as with, say, fluoxetine with its three fluorines but six months seems extremely long. I&#x27;d have thought it&#x27;d have been flushed out long before that. Presumably, it must bind to lipids, fats etc.<p>Anyway, whatever, it&#x27;s clearly a brilliant bit of chem eng.</div><br/></div></div></div></div><div id="41187865" class="c"><input type="checkbox" id="c-41187865" checked=""/><div class="controls bullet"><span class="by">mensetmanusman</span><span>|</span><a href="#41185700">root</a><span>|</span><a href="#41186163">parent</a><span>|</span><a href="#41186226">prev</a><span>|</span><a href="#41188716">next</a><span>|</span><label class="collapse" for="c-41187865">[-]</label><label class="expand" for="c-41187865">[7 more]</label></div><br/><div class="children"><div class="content">The drug is a PFAS (as nearly half of new drugs are), so it can act that way in the body.</div><br/><div id="41188452" class="c"><input type="checkbox" id="c-41188452" checked=""/><div class="controls bullet"><span class="by">FooBarWidget</span><span>|</span><a href="#41185700">root</a><span>|</span><a href="#41187865">parent</a><span>|</span><a href="#41188716">next</a><span>|</span><label class="collapse" for="c-41188452">[-]</label><label class="expand" for="c-41188452">[6 more]</label></div><br/><div class="children"><div class="content">I thought PFAS are toxic?</div><br/><div id="41188970" class="c"><input type="checkbox" id="c-41188970" checked=""/><div class="controls bullet"><span class="by">PetitPrince</span><span>|</span><a href="#41185700">root</a><span>|</span><a href="#41188452">parent</a><span>|</span><a href="#41188602">next</a><span>|</span><label class="collapse" for="c-41188970">[-]</label><label class="expand" for="c-41188970">[3 more]</label></div><br/><div class="children"><div class="content">PFAS only describe one part of the overall molecule. It doesn&#x27;t necessarily tells if the rest of the structure is toxic or not. It&#x27;s like saying &quot;I though canine were dangerous?&quot; (yes for big cats, no so much for your average French bulldog).<p>Also, the dose makes the poison, etc.</div><br/><div id="41189251" class="c"><input type="checkbox" id="c-41189251" checked=""/><div class="controls bullet"><span class="by">Twisol</span><span>|</span><a href="#41185700">root</a><span>|</span><a href="#41188970">parent</a><span>|</span><a href="#41188602">next</a><span>|</span><label class="collapse" for="c-41189251">[-]</label><label class="expand" for="c-41189251">[2 more]</label></div><br/><div class="children"><div class="content">&gt; It&#x27;s like saying &quot;I though canine were dangerous?&quot; (yes for big cats, no so much for your average French bulldog).<p>Big cats are not canines :(</div><br/><div id="41189444" class="c"><input type="checkbox" id="c-41189444" checked=""/><div class="controls bullet"><span class="by">mangamadaiyan</span><span>|</span><a href="#41185700">root</a><span>|</span><a href="#41189251">parent</a><span>|</span><a href="#41188602">next</a><span>|</span><label class="collapse" for="c-41189444">[-]</label><label class="expand" for="c-41189444">[1 more]</label></div><br/><div class="children"><div class="content">Cats, big as well as small, are feline :)</div><br/></div></div></div></div></div></div><div id="41188602" class="c"><input type="checkbox" id="c-41188602" checked=""/><div class="controls bullet"><span class="by">amarant</span><span>|</span><a href="#41185700">root</a><span>|</span><a href="#41188452">parent</a><span>|</span><a href="#41188970">prev</a><span>|</span><a href="#41188960">next</a><span>|</span><label class="collapse" for="c-41188602">[-]</label><label class="expand" for="c-41188602">[1 more]</label></div><br/><div class="children"><div class="content">It&#x27;s somewhat unclear, but given that they&#x27;ve been found in every piece of human tissue tested for it, I&#x27;d say at the very least it kills slower than HIV. Of course there are many different kinds of PFAS, some might be worse than others.</div><br/></div></div><div id="41188960" class="c"><input type="checkbox" id="c-41188960" checked=""/><div class="controls bullet"><span class="by">vasco</span><span>|</span><a href="#41185700">root</a><span>|</span><a href="#41188452">parent</a><span>|</span><a href="#41188602">prev</a><span>|</span><a href="#41188716">next</a><span>|</span><label class="collapse" for="c-41188960">[-]</label><label class="expand" for="c-41188960">[1 more]</label></div><br/><div class="children"><div class="content">Most vaccines have had some toxic component in them particularly historicaly. If you look up different vaccine types over the past 50 years you&#x27;ll see often ingredients are removed or replaced because of it. The general wisdom is that it&#x27;s either small enough quantities that you&#x27;d have less negatives from the toxicity than you have from being able to prevent the disease at a population level.</div><br/></div></div></div></div></div></div><div id="41188716" class="c"><input type="checkbox" id="c-41188716" checked=""/><div class="controls bullet"><span class="by">14</span><span>|</span><a href="#41185700">root</a><span>|</span><a href="#41186163">parent</a><span>|</span><a href="#41187865">prev</a><span>|</span><a href="#41188005">next</a><span>|</span><label class="collapse" for="c-41188716">[-]</label><label class="expand" for="c-41188716">[1 more]</label></div><br/><div class="children"><div class="content">I would have thought that too but at one point I had clients taking a bone loss drug called Alendronate. Looking up the drug I was shocked to see that it has a 10 year half life in bone tissue. So yes some drugs once taken will stay in certain tissues for a very long time.</div><br/></div></div><div id="41188005" class="c"><input type="checkbox" id="c-41188005" checked=""/><div class="controls bullet"><span class="by">refurb</span><span>|</span><a href="#41185700">root</a><span>|</span><a href="#41186163">parent</a><span>|</span><a href="#41188716">prev</a><span>|</span><a href="#41186842">next</a><span>|</span><label class="collapse" for="c-41188005">[-]</label><label class="expand" for="c-41188005">[1 more]</label></div><br/><div class="children"><div class="content">&gt; Surely this molecule can&#x27;t just hang around for six months without being gobbled up by the liver or such.<p>It can!  The fluorines likely protect the metabolic target.  At that point you&#x27;re relying on excretion of unchanged drug through the kidneys or liver (which excrete into bile, and then eliminated in feces).<p>Google tells me the half-life of the subcutaneous administration is 2 to 3 months, so twice yearly injections makes sense.</div><br/></div></div></div></div><div id="41186842" class="c"><input type="checkbox" id="c-41186842" checked=""/><div class="controls bullet"><span class="by">rlad</span><span>|</span><a href="#41185700">root</a><span>|</span><a href="#41185777">parent</a><span>|</span><a href="#41186163">prev</a><span>|</span><a href="#41187672">next</a><span>|</span><label class="collapse" for="c-41186842">[-]</label><label class="expand" for="c-41186842">[4 more]</label></div><br/><div class="children"><div class="content">No problem with this is it it does not interfere with infection. Only with replication. So it will not stop people from becoming infected.</div><br/><div id="41186905" class="c"><input type="checkbox" id="c-41186905" checked=""/><div class="controls bullet"><span class="by">sddsdd</span><span>|</span><a href="#41185700">root</a><span>|</span><a href="#41186842">parent</a><span>|</span><a href="#41187282">next</a><span>|</span><label class="collapse" for="c-41186905">[-]</label><label class="expand" for="c-41186905">[1 more]</label></div><br/><div class="children"><div class="content">It does in fact prevent infection you have misunderstood.<p>It very clearly prevents infection incredibly well, proof of that in the real world is exactly why there is excitement over this drug.<p>It also sounds as though you misunderstood the mechanism, it interferes in both an early and a late step in the viral process, there no theoretical reason to describe it as &quot;not interfering with infection&quot;.</div><br/></div></div><div id="41187282" class="c"><input type="checkbox" id="c-41187282" checked=""/><div class="controls bullet"><span class="by">scotty79</span><span>|</span><a href="#41185700">root</a><span>|</span><a href="#41186842">parent</a><span>|</span><a href="#41186905">prev</a><span>|</span><a href="#41188660">next</a><span>|</span><label class="collapse" for="c-41187282">[-]</label><label class="expand" for="c-41187282">[1 more]</label></div><br/><div class="children"><div class="content">There&#x27;s no infection without replication.</div><br/></div></div><div id="41188660" class="c"><input type="checkbox" id="c-41188660" checked=""/><div class="controls bullet"><span class="by">sfn42</span><span>|</span><a href="#41185700">root</a><span>|</span><a href="#41186842">parent</a><span>|</span><a href="#41187282">prev</a><span>|</span><a href="#41187672">next</a><span>|</span><label class="collapse" for="c-41188660">[-]</label><label class="expand" for="c-41188660">[1 more]</label></div><br/><div class="children"><div class="content">Infection is when the virus replicates faster than the body can eliminate it.</div><br/></div></div></div></div></div></div><div id="41187672" class="c"><input type="checkbox" id="c-41187672" checked=""/><div class="controls bullet"><span class="by">nobody9999</span><span>|</span><a href="#41185700">parent</a><span>|</span><a href="#41185777">prev</a><span>|</span><a href="#41185536">next</a><span>|</span><label class="collapse" for="c-41187672">[-]</label><label class="expand" for="c-41187672">[3 more]</label></div><br/><div class="children"><div class="content">&gt;There&#x27;s always the risk of losing previously effective drugs due to resistance, so the value of redundancy cannot be overstated<p>Redundancy in HIV drugs is <i>extremely</i> important and significantly more resources should be applied to such drugs, as well as to treatment regimens and vaccines that can significantly reduce HIV infection and the horrible effects of AIDS.<p>In fact, we&#x27;ve made enormous advances over the past 35+ years.  My (late) sister&#x27;s (late) husband was a hemophiliac and, like most American hemophiliacs[0], was infected with HIV because big pharma refused to test the blood products[1] they were <i>selling</i> to hemophiliacs, even though they knew there was a significant risk in doing so.<p>In any case, my sister took care of her husband for nearly 15 years, until he finally died a slow, painful death in 1996.  My sister was also HIV+ and didn&#x27;t wish to suffer the way her husband had, especially since there was no one to care for her the way she cared for him.  And so, over Memorial Day weekend, 1996, my sister took her own life rather than die a slow, painful death.<p>The irony, of course, was that the first protease inhibitors were approved by the FDA five or six months later.  Had she waited, she might well be alive today.  And more&#x27;s the pity.<p>As such, I strongly believe in research to prevent, treat and cure HIV&#x2F;AIDS, and heartily agree that we need more good drugs and treatments.<p>However, the value of anything <i>can</i> be overstated, including redundancy in HIV drugs.<p>&quot;Without significant redundancy in HIV drugs, all life in the universe will be extinguished.&quot;<p>&quot;Without significant redundancy in HIV drugs, our sun will explode in 2043.&quot;<p>&quot;Without significant redundancy in HIV drugs, the oceans will boil, then evaporate in the next six weeks.&quot;<p>I could go on, but I presume you get the idea.<p>Hyperbole can be a short-term motivator, but we need to continue over the long term to stop HIV&#x2F;AIDS.  So, please do advocate for more research&#x2F;drugs&#x2F;treatments, but please don&#x27;t use such language in doing so -- it cheapens the argument and potentially reduces the resources available for the efforts you clearly want.<p>Feel free to disagree, but doing so will give you terminal cancer.[2]<p>[0] <a href="https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC2917149&#x2F;" rel="nofollow">https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC2917149&#x2F;</a><p>[1] <a href="https:&#x2F;&#x2F;www.cbsnews.com&#x2F;news&#x2F;bayer-says-it-settled-decades-old-hiv-tainted-blood-cases&#x2F;" rel="nofollow">https:&#x2F;&#x2F;www.cbsnews.com&#x2F;news&#x2F;bayer-says-it-settled-decades-o...</a><p>[2] See what I did there?</div><br/><div id="41188908" class="c"><input type="checkbox" id="c-41188908" checked=""/><div class="controls bullet"><span class="by">jart</span><span>|</span><a href="#41185700">root</a><span>|</span><a href="#41187672">parent</a><span>|</span><a href="#41188543">next</a><span>|</span><label class="collapse" for="c-41188908">[-]</label><label class="expand" for="c-41188908">[1 more]</label></div><br/><div class="children"><div class="content">&gt; Redundancy in HIV drugs is extremely important and significantly more resources should be applied to such drugs<p>Does HIV prevention research get more resources than curing cancer? I&#x27;m looking through the NIH website and asking Claude and so far the evidence I&#x27;ve seen is leading me to believe that&#x27;s true, but I could be mistaken.</div><br/></div></div><div id="41188543" class="c"><input type="checkbox" id="c-41188543" checked=""/><div class="controls bullet"><span class="by">cossatot</span><span>|</span><a href="#41185700">root</a><span>|</span><a href="#41187672">parent</a><span>|</span><a href="#41188908">prev</a><span>|</span><a href="#41185536">next</a><span>|</span><label class="collapse" for="c-41188543">[-]</label><label class="expand" for="c-41188543">[1 more]</label></div><br/><div class="children"><div class="content">Iâm sorry your family was put through so much termoil.</div><br/></div></div></div></div></div></div><div id="41185536" class="c"><input type="checkbox" id="c-41185536" checked=""/><div class="controls bullet"><span class="by">thisrod</span><span>|</span><a href="#41185700">prev</a><span>|</span><a href="#41185115">next</a><span>|</span><label class="collapse" for="c-41185536">[-]</label><label class="expand" for="c-41185536">[78 more]</label></div><br/><div class="children"><div class="content">I wonder how much this will cost?  A drug you take 2 times a year could be much cheaper than one you take 365 times a year, and that&#x27;s a big deal.<p>The existing daily pill is really expensive.  Australia knew that PrEP would practically eliminate HIV transmission.  Even so, the decision to pay for it took years and was fiercely contested.  That was before COVID, and people are more willing to pay for public health today.  But cheap PReP would make a big difference in the poor countries where HIV prevention really matters.</div><br/><div id="41185814" class="c"><input type="checkbox" id="c-41185814" checked=""/><div class="controls bullet"><span class="by">argonaut</span><span>|</span><a href="#41185536">parent</a><span>|</span><a href="#41187706">next</a><span>|</span><label class="collapse" for="c-41185814">[-]</label><label class="expand" for="c-41185814">[75 more]</label></div><br/><div class="children"><div class="content">The shot will likely be exorbitant in the USA. Gilead charged almost $2k&#x2F;month for Truvada (list price, of course) and Descovy is the same. Generic Truvada is like $30&#x2F;month now, so the price was never about the cost to manufacture. Obviously Gilead is developing these new drugs&#x2F;shots for when Descovy&#x27;s patent expires.<p>They rely on the government mandating that health insurance companies cover the shots. This drives up the price.</div><br/><div id="41185875" class="c"><input type="checkbox" id="c-41185875" checked=""/><div class="controls bullet"><span class="by">ortusdux</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185814">parent</a><span>|</span><a href="#41188846">next</a><span>|</span><label class="collapse" for="c-41185875">[-]</label><label class="expand" for="c-41185875">[31 more]</label></div><br/><div class="children"><div class="content">The price is rarely ever about the manufacturing cost.<p>&quot;A new study in 2020 estimated that the median cost of getting a new drug into the market was $985 million, and the average cost was $1.3 billion, which was much lower compared to previous studies, which have placed the average cost of drug development as $2.8 billion.[4]&quot;<p><a href="https:&#x2F;&#x2F;en.wikipedia.org&#x2F;wiki&#x2F;Cost_of_drug_development" rel="nofollow">https:&#x2F;&#x2F;en.wikipedia.org&#x2F;wiki&#x2F;Cost_of_drug_development</a></div><br/><div id="41186331" class="c"><input type="checkbox" id="c-41186331" checked=""/><div class="controls bullet"><span class="by">pfdietz</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185875">parent</a><span>|</span><a href="#41188028">next</a><span>|</span><label class="collapse" for="c-41186331">[-]</label><label class="expand" for="c-41186331">[15 more]</label></div><br/><div class="children"><div class="content">It should be pointed out that looking at the average cost of developing a drug is misleading, since one has to include the cost of all the drugs that failed to make it to market.  One also has to include the money spent by small companies that failed and were not bought out, not just the money the big companies spend buying the successful ones.</div><br/><div id="41186423" class="c"><input type="checkbox" id="c-41186423" checked=""/><div class="controls bullet"><span class="by">Nifty3929</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186331">parent</a><span>|</span><a href="#41186891">next</a><span>|</span><label class="collapse" for="c-41186423">[-]</label><label class="expand" for="c-41186423">[4 more]</label></div><br/><div class="children"><div class="content">This is critical, and exactly the sort of thing someone will gloss over, intentionally or not. The numerator is the total cost of developing ALL the drugs, even (especially) the failed ones, but the denominator is only those drugs that are successful.</div><br/><div id="41187126" class="c"><input type="checkbox" id="c-41187126" checked=""/><div class="controls bullet"><span class="by">FireBeyond</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186423">parent</a><span>|</span><a href="#41186891">next</a><span>|</span><label class="collapse" for="c-41187126">[-]</label><label class="expand" for="c-41187126">[3 more]</label></div><br/><div class="children"><div class="content">On the contrary, often pharma proponents will gloss over the fact that most âfailuresâ are discovered and canned at a small fraction of the investment of getting a drug to market (when itâs obvious it wonât do what you need or has other challenges).<p>Actually not in the contrary - you are right. Itâs just that the failures often cost a small fraction. They donât get to 95% testing and approval before ânope, not even closeâ.</div><br/><div id="41187415" class="c"><input type="checkbox" id="c-41187415" checked=""/><div class="controls bullet"><span class="by">pfdietz</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41187126">parent</a><span>|</span><a href="#41186891">next</a><span>|</span><label class="collapse" for="c-41187415">[-]</label><label class="expand" for="c-41187415">[2 more]</label></div><br/><div class="children"><div class="content">I understand 60% of drug candidates fail in phase 3, the last and most expensive phase of testing.<p>There are of course lots of chemicals ruled out early, but that&#x27;s before you have something you&#x27;d call a drug.</div><br/><div id="41188127" class="c"><input type="checkbox" id="c-41188127" checked=""/><div class="controls bullet"><span class="by">FireBeyond</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41187415">parent</a><span>|</span><a href="#41186891">next</a><span>|</span><label class="collapse" for="c-41188127">[-]</label><label class="expand" for="c-41188127">[1 more]</label></div><br/><div class="children"><div class="content">No, that&#x27;s not quite accurate - the phases are effectively additive.<p>37% fail in Phase 1. Of those that make it through, 69% of those fail in Phase 2, and of those, 42% fail in Phase 3.<p>So, of 1,000 possibles, you have 630 make it through Phase 1, and 195 that make it through phase 2, i.e. 80.5% of your drug candidates didn&#x27;t even make it to Phase 3, that &quot;most expensive phase&quot;.<p>A more accurate phrasing would be that 42% <i>of the drugs that made it through Phase 2</i> fail to make it through Phase 3.</div><br/></div></div></div></div></div></div></div></div><div id="41186891" class="c"><input type="checkbox" id="c-41186891" checked=""/><div class="controls bullet"><span class="by">tbrownaw</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186331">parent</a><span>|</span><a href="#41186423">prev</a><span>|</span><a href="#41186632">next</a><span>|</span><label class="collapse" for="c-41186891">[-]</label><label class="expand" for="c-41186891">[9 more]</label></div><br/><div class="children"><div class="content">&gt; <i>One also has to include the money spent by small companies that failed and were not bought out, not just the money the big companies spend buying the successful ones.</i><p>If you&#x27;re looking at the total amount spent by &quot;the economy&quot; (drug development costs X% of GDP), sure. If you&#x27;re looking at &quot;why are drug prices so high&quot;, it probably doesn&#x27;t make sense to to include costs funded from other places (which in this example I assume would be research grants ie taxes, and venture capital funds).</div><br/><div id="41187055" class="c"><input type="checkbox" id="c-41187055" checked=""/><div class="controls bullet"><span class="by">mlyle</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186891">parent</a><span>|</span><a href="#41186986">next</a><span>|</span><label class="collapse" for="c-41187055">[-]</label><label class="expand" for="c-41187055">[3 more]</label></div><br/><div class="children"><div class="content">For the private parts of development, the costs are absolutely priced in.  A large drug company needs to amortize the cost of all development attempts, not just the successful ones.  Private investments into smaller firms price in a very large chance of failure, so the cost of capital is quite high.</div><br/><div id="41187177" class="c"><input type="checkbox" id="c-41187177" checked=""/><div class="controls bullet"><span class="by">pfdietz</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41187055">parent</a><span>|</span><a href="#41186986">next</a><span>|</span><label class="collapse" for="c-41187177">[-]</label><label class="expand" for="c-41187177">[2 more]</label></div><br/><div class="children"><div class="content">That&#x27;s not quite right.  A drug company with a new product will charge whatever the market will bear.  What the costs do is control the scope of the industry:  if profits are high, the industry expands to try more kinds of drugs, stopping when the attempts on the margin are just profitable enough (on average).  If profits are not expected to be adequate, the industry contracts.</div><br/><div id="41187451" class="c"><input type="checkbox" id="c-41187451" checked=""/><div class="controls bullet"><span class="by">mlyle</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41187177">parent</a><span>|</span><a href="#41186986">next</a><span>|</span><label class="collapse" for="c-41187451">[-]</label><label class="expand" for="c-41187451">[1 more]</label></div><br/><div class="children"><div class="content">That&#x27;s close to what I tried to say.<p>Perhaps you prefer: A company must think it&#x27;s likely that they&#x27;ll have a good return on all development costs, not just the costs of drugs that happen to be successful, to continue to invest.<p>&gt; if profits are high, the industry expands to try more kinds of drugs, stopping when the attempts on the margin are just profitable enough (on average).<p>Of course, something like pharmaceutical products, with exclusive sales of specific products, few sellers, strategic conduct relative to other industries (insurers), and heavy regulatory influence is not guaranteed to converge to normal profit.</div><br/></div></div></div></div></div></div><div id="41186986" class="c"><input type="checkbox" id="c-41186986" checked=""/><div class="controls bullet"><span class="by">JoelEinbinder</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186891">parent</a><span>|</span><a href="#41187055">prev</a><span>|</span><a href="#41186632">next</a><span>|</span><label class="collapse" for="c-41186986">[-]</label><label class="expand" for="c-41186986">[5 more]</label></div><br/><div class="children"><div class="content">I&#x27;m not going to invest a drug company with a 90% chance of failure unless I can expect to get a 10x return if it succeeds.</div><br/><div id="41187108" class="c"><input type="checkbox" id="c-41187108" checked=""/><div class="controls bullet"><span class="by">FireBeyond</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186986">parent</a><span>|</span><a href="#41186632">next</a><span>|</span><label class="collapse" for="c-41187108">[-]</label><label class="expand" for="c-41187108">[4 more]</label></div><br/><div class="children"><div class="content">The problem with this argument is it assumes the cost of a failure is the same as the cost of success, which it cannot be: the successful drug has to go through more rounds of testing and approvals than a failure.<p>In reality many failures are early or first round failures. Not free but a small fraction of the price of getting to market.<p>So to you example a 90% failure rate may only require a 2x or 3x return on your successes to âbreak evenâ.</div><br/><div id="41187718" class="c"><input type="checkbox" id="c-41187718" checked=""/><div class="controls bullet"><span class="by">refurb</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41187108">parent</a><span>|</span><a href="#41186632">next</a><span>|</span><label class="collapse" for="c-41187718">[-]</label><label class="expand" for="c-41187718">[3 more]</label></div><br/><div class="children"><div class="content">Clinical trial failure rates (or inversely success rates) have been analyzed before.<p><a href="https:&#x2F;&#x2F;www.nature.com&#x2F;articles&#x2F;nrd.2016.136" rel="nofollow">https:&#x2F;&#x2F;www.nature.com&#x2F;articles&#x2F;nrd.2016.136</a><p><i>&quot;They found that the probability of success was 63% in Phase I trials, 31% in Phase II trials, 58% in Phase III trials and 85% during the regulatory review process&quot;</i><p>42% failure rates in phase 3 is enormously high.  By then you&#x27;ve pretty much spent 90%+ of all the cost of getting a drug approved.</div><br/><div id="41188144" class="c"><input type="checkbox" id="c-41188144" checked=""/><div class="controls bullet"><span class="by">FireBeyond</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41187718">parent</a><span>|</span><a href="#41186632">next</a><span>|</span><label class="collapse" for="c-41188144">[-]</label><label class="expand" for="c-41188144">[2 more]</label></div><br/><div class="children"><div class="content">But it&#x27;s 42% of 19%. So out of 1,000 drugs, you&#x27;re looking at 805 being ruled out before you even get to that &quot;most expensive phase&quot;, which is my point. At Phase 3, you&#x27;re looking at 113 succeeding, so you&#x27;re &quot;only&quot; eating the really expensive[1] costs of Phase 3 for 82[2] of 1,000 attempts.<p>[1] Which isn&#x27;t to say there&#x27;s zero cost for Phase 1 or Phase 2, but it&#x27;s a lot lot less than Phase 3 trials.<p>[2] 1,000 drugs, 63%, 630 of which make it through Phase 1. In Phase 2, 195 drugs, 31% of 630 succeed and make it through to Phase 3, and then 82 drugs (58% of 195) make it to regulatory approval.</div><br/><div id="41188568" class="c"><input type="checkbox" id="c-41188568" checked=""/><div class="controls bullet"><span class="by">refurb</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41188144">parent</a><span>|</span><a href="#41186632">next</a><span>|</span><label class="collapse" for="c-41188568">[-]</label><label class="expand" for="c-41188568">[1 more]</label></div><br/><div class="children"><div class="content">Right, but with the cost distribution for clinical trials, costs increase by 4x in phase 2, then 8x in phase 3 (relative to phase 1).<p>So despite attrition that reduces candidates by 9x by phase 3, costs have increased by 8x.<p>[1]<a href="https:&#x2F;&#x2F;www.sofpromed.com&#x2F;how-much-does-a-clinical-trial-cost" rel="nofollow">https:&#x2F;&#x2F;www.sofpromed.com&#x2F;how-much-does-a-clinical-trial-cos...</a></div><br/></div></div></div></div></div></div></div></div></div></div></div></div></div></div><div id="41188028" class="c"><input type="checkbox" id="c-41188028" checked=""/><div class="controls bullet"><span class="by">rishav_sharan</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185875">parent</a><span>|</span><a href="#41186331">prev</a><span>|</span><a href="#41186071">next</a><span>|</span><label class="collapse" for="c-41188028">[-]</label><label class="expand" for="c-41188028">[1 more]</label></div><br/><div class="children"><div class="content">Talking of studies, from the same wiki<p><pre><code>   A 2022 study invalidated the common argument as is for high medication costs that research and development investments are reflected in and necessitate the treatment costs, finding no correlation for investments in drugs (for cases where transparency was sufficient) and their costs.[20][21]</code></pre></div><br/></div></div><div id="41186071" class="c"><input type="checkbox" id="c-41186071" checked=""/><div class="controls bullet"><span class="by">chimeracoder</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185875">parent</a><span>|</span><a href="#41188028">prev</a><span>|</span><a href="#41187377">next</a><span>|</span><label class="collapse" for="c-41186071">[-]</label><label class="expand" for="c-41186071">[13 more]</label></div><br/><div class="children"><div class="content">&gt; &quot;A new study in 2020 estimated that the median cost of getting a new drug into the market was $985 million, and the average cost was $1.3 billion, which was much lower compared to previous studies, which have placed the average cost of drug development as $2.8 billion.[4]&quot;<p>PrEP repurposed Truvada, an existing blockbuster drug that had already reaped immense profit for Gilead for use in HIV treatment by the time the trials for PrEP began. The trials for PrEP were funded by the government, not Gilead. Gilead, however, got to retain all profits earned from PrEP.</div><br/><div id="41186358" class="c"><input type="checkbox" id="c-41186358" checked=""/><div class="controls bullet"><span class="by">ortusdux</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186071">parent</a><span>|</span><a href="#41186087">next</a><span>|</span><label class="collapse" for="c-41186358">[-]</label><label class="expand" for="c-41186358">[2 more]</label></div><br/><div class="children"><div class="content">A significant portion of the cost is the drug trials.  Excedrin Extra Strength and Excedrin Migraine have identical formulations, but IIRC Bayer spent $300m on FDA approval for migraine treatment, which is why the migraine variant continues to be more expensive.</div><br/><div id="41186913" class="c"><input type="checkbox" id="c-41186913" checked=""/><div class="controls bullet"><span class="by">chimeracoder</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186358">parent</a><span>|</span><a href="#41186087">next</a><span>|</span><label class="collapse" for="c-41186913">[-]</label><label class="expand" for="c-41186913">[1 more]</label></div><br/><div class="children"><div class="content">&gt; 
A significant portion of the cost is the drug trials. Excedrin Extra Strength and Excedrin Migraine have identical formulations, but IIRC Bayer spent $300m on FDA approval for migraine treatment, which is why the migraine variant continues to be more expensive.<p>Your analogy would only be relevant if the US government paid $300M for the FDA approval and Bayer got to pocket 100% of the markup.</div><br/></div></div></div></div><div id="41186087" class="c"><input type="checkbox" id="c-41186087" checked=""/><div class="controls bullet"><span class="by">HideousKojima</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186071">parent</a><span>|</span><a href="#41186358">prev</a><span>|</span><a href="#41187377">next</a><span>|</span><label class="collapse" for="c-41186087">[-]</label><label class="expand" for="c-41186087">[10 more]</label></div><br/><div class="children"><div class="content">Did Gilead fund the R&amp;D? There&#x27;s a lot more to developing a new drug than just trials (though I think Gilead should have foot the bill for the trials too).</div><br/><div id="41186171" class="c"><input type="checkbox" id="c-41186171" checked=""/><div class="controls bullet"><span class="by">roughly</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186087">parent</a><span>|</span><a href="#41187377">next</a><span>|</span><label class="collapse" for="c-41186171">[-]</label><label class="expand" for="c-41186171">[9 more]</label></div><br/><div class="children"><div class="content">I donât know if itâs the case here, but very, very, very often in biotech youâve got the primary foundational research happening at university labs funded by grants, and itâs the productionization of the research (and then clinical trials, etc) that are what the biotech companies are doing. Iâm not sure where that shifts the âwho deserves whatâ conversation, but without university research labs, thereâs no pharma industry.</div><br/><div id="41186369" class="c"><input type="checkbox" id="c-41186369" checked=""/><div class="controls bullet"><span class="by">pfdietz</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186171">parent</a><span>|</span><a href="#41186451">next</a><span>|</span><label class="collapse" for="c-41186369">[-]</label><label class="expand" for="c-41186369">[2 more]</label></div><br/><div class="children"><div class="content">If the university owned the IP, then its value should have been reflected in what was bid for it.<p>If the knowledge was not restricted by IP law, then any drug company could use it, and compete for new drugs based on it.  As such, it would not provide any of them with a competitive advantage, and so would not be reflected in what they could charge.<p>What universities typically produce is not a chemical that can serve as an actual drug, but is only a starting point for a long and expensive process of producing such a chemical.  And then, it&#x27;s often found that the target of the class of potential drugs isn&#x27;t actually a good one.  One can&#x27;t determine that until drug candidates are available to test on real patients.</div><br/><div id="41186699" class="c"><input type="checkbox" id="c-41186699" checked=""/><div class="controls bullet"><span class="by">Jensson</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186369">parent</a><span>|</span><a href="#41186451">next</a><span>|</span><label class="collapse" for="c-41186699">[-]</label><label class="expand" for="c-41186699">[1 more]</label></div><br/><div class="children"><div class="content">&gt; What universities typically produce is not a chemical that can serve as an actual drug, but is only a starting point for a long and expensive process of producing such a chemical<p>Remember you need to include all the failed attempts at finding useful things at university labs to see how much governments spend on research (just like you did failed pharma attempts), and if you add that up you see governments actually contribute a massive part of the cost to bring medicines to market.<p>What they produce is necessary to even begin the work pharma does, currently it is basically a gift from the people to the pharma industry.</div><br/></div></div></div></div><div id="41186451" class="c"><input type="checkbox" id="c-41186451" checked=""/><div class="controls bullet"><span class="by">Nifty3929</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186171">parent</a><span>|</span><a href="#41186369">prev</a><span>|</span><a href="#41187340">next</a><span>|</span><label class="collapse" for="c-41186451">[-]</label><label class="expand" for="c-41186451">[3 more]</label></div><br/><div class="children"><div class="content">&quot;without university research labs, thereâs no pharma industry.&quot; - I think you have it exactly backwards: Without the pharma industry, there&#x27;s no medicine. Good research goes nowhere if you can&#x27;t bring it to market.<p>The pharma industry COULD do their own foundational research, but the university system cannot bring a drug to market.</div><br/><div id="41186683" class="c"><input type="checkbox" id="c-41186683" checked=""/><div class="controls bullet"><span class="by">Jensson</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186451">parent</a><span>|</span><a href="#41187146">next</a><span>|</span><label class="collapse" for="c-41186683">[-]</label><label class="expand" for="c-41186683">[1 more]</label></div><br/><div class="children"><div class="content">&gt; The pharma industry COULD do their own foundational research, but the university system cannot bring a drug to market.<p>You can&#x27;t use an &quot;in theory&quot; argument for one side but not the other.<p>In theory governments could bring medicine to market, in practice they don&#x27;t&#x2F;can&#x27;t.<p>In theory pharma industry could do foundational research, but in practice they don&#x27;t&#x2F;can&#x27;t.</div><br/></div></div><div id="41187146" class="c"><input type="checkbox" id="c-41187146" checked=""/><div class="controls bullet"><span class="by">FireBeyond</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186451">parent</a><span>|</span><a href="#41186683">prev</a><span>|</span><a href="#41187340">next</a><span>|</span><label class="collapse" for="c-41187146">[-]</label><label class="expand" for="c-41187146">[1 more]</label></div><br/><div class="children"><div class="content">If thereâs no pharma industry?<p>You act like the solution would be âoh well, no meds for anyone then!â and not âletâs expand university programs to meet that needâ.</div><br/></div></div></div></div><div id="41187340" class="c"><input type="checkbox" id="c-41187340" checked=""/><div class="controls bullet"><span class="by">a-dub</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186171">parent</a><span>|</span><a href="#41186451">prev</a><span>|</span><a href="#41187489">next</a><span>|</span><label class="collapse" for="c-41187340">[-]</label><label class="expand" for="c-41187340">[2 more]</label></div><br/><div class="children"><div class="content">i&#x27;ve always viewed big pharma as like pre-internet record labels. they pick up talent (that often comes from bohemia aka government funded research), vet it, run the trials and put up the money, do the engineering to deliver it at scale and then market it.</div><br/><div id="41187890" class="c"><input type="checkbox" id="c-41187890" checked=""/><div class="controls bullet"><span class="by">mensetmanusman</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41187340">parent</a><span>|</span><a href="#41187489">next</a><span>|</span><label class="collapse" for="c-41187890">[-]</label><label class="expand" for="c-41187890">[1 more]</label></div><br/><div class="children"><div class="content">Thatâs also like any endeavor with tech.</div><br/></div></div></div></div><div id="41187489" class="c"><input type="checkbox" id="c-41187489" checked=""/><div class="controls bullet"><span class="by">wdwvt1</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186171">parent</a><span>|</span><a href="#41187340">prev</a><span>|</span><a href="#41187377">next</a><span>|</span><label class="collapse" for="c-41187489">[-]</label><label class="expand" for="c-41187489">[1 more]</label></div><br/><div class="children"><div class="content">The direct role that university research plays in drug development is overstated. The majority of cost and difficulty in pharma is _drug development_ not _drug discovery_. Pharma can do the discovery and the development, academics can only do the development. Absent academia, we&#x27;d have less drugs. Absent pharma we&#x27;d have no drugs.<p>Academics focus on drug discovery because it&#x27;s better aligned with academic incentives and timelines (see this commentary for a brief description [0]). Drug development costs (including clinical trials, extensive and repeated med chem, etc) are borne mostly by drug companies.<p>Fair data on this is hard to come by because the two main sources have clear conflicts of interest (academics and pharma industry publications). One study Derek covered before (data from 1995-2007) shows only 24% of drug scaffolds were first found at a university and transferred to a biotech or pharma for development [1]. You can break this down further to highlight any story you want to support (&#x27;university ID&#x27;d drugs more innovative&#x27; vs. &#x27;pharma ID&#x27;d drugs help more people&#x27;) but they key point is that combining all the US research leads to only 24% of drug scaffolds that make it to market.<p>I think everyone acknowledges that outside of finding the scaffolds and the basic biology, pharma is paying the vast majority of clinical trial costs. [2] gives a figure of total NIH funding of clinical trials at 10% of overall (e.g. pharma covers 90%).<p>I think an argument could be made that the NIH training grants (which pay grad students in the biomedical sciences) subsidize the work force substantially, and might have a higher impact than direct research grants. I couldn&#x27;t find quantitative data on this with a quick search, but I think this is often overlooked in the discussion.<p>Finally, a less quantitative pieces make me think the impact of the NIH&#x2F;government funding is overstated even given the above numbers. In my own field (microbiome), academic research has been almost inimical to the production of quality drugs. For every disease there exists a paper suggesting that a certain gut microbe changes the likelihood&#x2F;severity&#x2F;X about that disease. Academic labs have incentives to publish significant results fast, and in the microbiome this has led to a) abysmal signal to noise ratio with very high likelihood of failure to replicate, and b) an epistemic closure about what types of microbiome data matter and how they should be pursued as drugs that is totally divorced from the reality of how drugs are developed. Much of the knowledge base is polluted by low-quality research that has been done for the purpose of publishing. While the NIH spends ~40 billion a year on external research grants [3], I think you have to heavily discount this for the amount of just pure &quot;grad student needs to graduate gotta publish&quot; material that gets produced.<p>[0] <a href="https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC10812233&#x2F;" rel="nofollow">https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC10812233&#x2F;</a>
[1] <a href="https:&#x2F;&#x2F;www.science.org&#x2F;content&#x2F;blog-post&#x2F;where-drugs-come-numbers" rel="nofollow">https:&#x2F;&#x2F;www.science.org&#x2F;content&#x2F;blog-post&#x2F;where-drugs-come-n...</a>
[2] <a href="https:&#x2F;&#x2F;www.fiercebiotech.com&#x2F;research&#x2F;report-industry-not-nih-fronts-most-cash-clinical-trials" rel="nofollow">https:&#x2F;&#x2F;www.fiercebiotech.com&#x2F;research&#x2F;report-industry-not-n...</a>
[3] <a href="https:&#x2F;&#x2F;www.nih.gov&#x2F;about-nih&#x2F;what-we-do&#x2F;budget" rel="nofollow">https:&#x2F;&#x2F;www.nih.gov&#x2F;about-nih&#x2F;what-we-do&#x2F;budget</a></div><br/></div></div></div></div></div></div></div></div><div id="41187377" class="c"><input type="checkbox" id="c-41187377" checked=""/><div class="controls bullet"><span class="by">hanniabu</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185875">parent</a><span>|</span><a href="#41186071">prev</a><span>|</span><a href="#41188846">next</a><span>|</span><label class="collapse" for="c-41187377">[-]</label><label class="expand" for="c-41187377">[1 more]</label></div><br/><div class="children"><div class="content">Also the government, aka the public, subsidizes a lot of those costs</div><br/></div></div></div></div><div id="41188846" class="c"><input type="checkbox" id="c-41188846" checked=""/><div class="controls bullet"><span class="by">modeless</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185814">parent</a><span>|</span><a href="#41185875">prev</a><span>|</span><a href="#41186128">next</a><span>|</span><label class="collapse" for="c-41188846">[-]</label><label class="expand" for="c-41188846">[5 more]</label></div><br/><div class="children"><div class="content">The patent system literally grants monopolies, on purpose. I don&#x27;t know why people are surprised when patented things are priced like there&#x27;s a monopoly exploiting their customers, because that&#x27;s exactly what&#x27;s happening and everyone knows it. But somehow people never seem to come to the conclusion that granting monopolies is not the ideal way to incentivize things.</div><br/><div id="41189000" class="c"><input type="checkbox" id="c-41189000" checked=""/><div class="controls bullet"><span class="by">vasco</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41188846">parent</a><span>|</span><a href="#41186128">next</a><span>|</span><label class="collapse" for="c-41189000">[-]</label><label class="expand" for="c-41189000">[4 more]</label></div><br/><div class="children"><div class="content">Maybe it is if the alternative is those things you granted monopoly on wouldn&#x27;t exist. With drugs especially it&#x27;s a difficult proposition to spend time researching if the day after you make your pill and sell the first one the next guy can just sell it too. So we need a larger change than just modifying the patent system for medicines, we&#x27;d also need to change the way we fund pharma research and after having thought about it a lot I don&#x27;t have a solution. I agree with the problem you mention, but the solution isn&#x27;t simple.</div><br/><div id="41189061" class="c"><input type="checkbox" id="c-41189061" checked=""/><div class="controls bullet"><span class="by">amrocha</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41189000">parent</a><span>|</span><a href="#41186128">next</a><span>|</span><label class="collapse" for="c-41189061">[-]</label><label class="expand" for="c-41189061">[3 more]</label></div><br/><div class="children"><div class="content">Thereâs no reason pharma research should be for profit. The researchers arenât doing it for profit, they would do it either way, the only thing private pharma brings to the table is price gouging.</div><br/><div id="41189112" class="c"><input type="checkbox" id="c-41189112" checked=""/><div class="controls bullet"><span class="by">vasco</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41189061">parent</a><span>|</span><a href="#41189158">next</a><span>|</span><label class="collapse" for="c-41189112">[-]</label><label class="expand" for="c-41189112">[1 more]</label></div><br/><div class="children"><div class="content">Citation needed on &quot;the researchers aren&#x27;t doing it for profit&quot;. All drug companies have a bunch of them, more than wall street types running around. Most of them enrich themselves with biotech stock bets, insider trading, regulatory capture of national agencies etc. Why do you think somehow people that go into pharma research are different from people in any other industry?<p>Look, random example <a href="https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC10370755&#x2F;" rel="nofollow">https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC10370755&#x2F;</a> - explain why if they are not motivated by profit, how is it possible that the outcome of this paper happens?<p>If you speak to anyone in the field, their goal to get to a point where you having a patent or two giving you a passive income stream. You can&#x27;t do it if you just public domain your work.</div><br/></div></div><div id="41189158" class="c"><input type="checkbox" id="c-41189158" checked=""/><div class="controls bullet"><span class="by">modeless</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41189061">parent</a><span>|</span><a href="#41189112">prev</a><span>|</span><a href="#41186128">next</a><span>|</span><label class="collapse" for="c-41189158">[-]</label><label class="expand" for="c-41189158">[1 more]</label></div><br/><div class="children"><div class="content">See, blaming private companies for the consequences of government-granted monopolies is exactly the kind of thing I don&#x27;t understand. The government is handing out permission to price gouge. On purpose!</div><br/></div></div></div></div></div></div></div></div><div id="41186128" class="c"><input type="checkbox" id="c-41186128" checked=""/><div class="controls bullet"><span class="by">bobthepanda</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185814">parent</a><span>|</span><a href="#41188846">prev</a><span>|</span><a href="#41188518">next</a><span>|</span><label class="collapse" for="c-41186128">[-]</label><label class="expand" for="c-41186128">[1 more]</label></div><br/><div class="children"><div class="content">There is a two-month shot now (Apretude) and I was quoted $4K a shot when I asked about it.<p>Health insurances in the US mostly only cover Truvada. Some cover Descovy but not many.</div><br/></div></div><div id="41188518" class="c"><input type="checkbox" id="c-41188518" checked=""/><div class="controls bullet"><span class="by">isoprophlex</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185814">parent</a><span>|</span><a href="#41186128">prev</a><span>|</span><a href="#41186868">next</a><span>|</span><label class="collapse" for="c-41188518">[-]</label><label class="expand" for="c-41188518">[1 more]</label></div><br/><div class="children"><div class="content">Crony capitalism at its best.</div><br/></div></div><div id="41186868" class="c"><input type="checkbox" id="c-41186868" checked=""/><div class="controls bullet"><span class="by">renewiltord</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185814">parent</a><span>|</span><a href="#41188518">prev</a><span>|</span><a href="#41185928">next</a><span>|</span><label class="collapse" for="c-41186868">[-]</label><label class="expand" for="c-41186868">[1 more]</label></div><br/><div class="children"><div class="content">Same with software. I saw IntelliJ costs $250&#x2F;year but it costs almost nothing to send that file (it&#x27;s like maybe 1 GB max, cents). You can get it from generics manufacturer on TPB but updates are not as frequent.</div><br/></div></div><div id="41185928" class="c"><input type="checkbox" id="c-41185928" checked=""/><div class="controls bullet"><span class="by">reducesuffering</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185814">parent</a><span>|</span><a href="#41186868">prev</a><span>|</span><a href="#41185899">next</a><span>|</span><label class="collapse" for="c-41185928">[-]</label><label class="expand" for="c-41185928">[12 more]</label></div><br/><div class="children"><div class="content">Like the other commenters allude to, how would you like software mandated to cost just 10% margin over COGS? Do you think selling cloud services for 10% more than the cost of server parts is going to be a business when there&#x27;s thousands of software engineers in R&amp;D needed?</div><br/><div id="41186090" class="c"><input type="checkbox" id="c-41186090" checked=""/><div class="controls bullet"><span class="by">LeifCarrotson</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185928">parent</a><span>|</span><a href="#41186809">next</a><span>|</span><label class="collapse" for="c-41186090">[-]</label><label class="expand" for="c-41186090">[2 more]</label></div><br/><div class="children"><div class="content">I would love that, as long as the cost includes that R&amp;D and those engineers, the actual bits might be immaterial but the engineer salaries are part of the cost of the goods.<p>The problem is that we&#x27;re being told that the cost of insulin is $270 per vial, or that Daraprim used to estimate its cost per dose at 90% of $13.50 and then Shkreli decided to raise it to $750.</div><br/><div id="41189029" class="c"><input type="checkbox" id="c-41189029" checked=""/><div class="controls bullet"><span class="by">vasco</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186090">parent</a><span>|</span><a href="#41186809">next</a><span>|</span><label class="collapse" for="c-41189029">[-]</label><label class="expand" for="c-41189029">[1 more]</label></div><br/><div class="children"><div class="content">The Shkreli case has nothing to do with the rest. He was playing the insurance companies and there isn&#x27;t a single person that went without the medicine due to the cost. Almost nobody takes this medicine.<p>In fact, it still costs $750 today.</div><br/></div></div></div></div><div id="41186809" class="c"><input type="checkbox" id="c-41186809" checked=""/><div class="controls bullet"><span class="by">pdntspa</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185928">parent</a><span>|</span><a href="#41186090">prev</a><span>|</span><a href="#41186948">next</a><span>|</span><label class="collapse" for="c-41186809">[-]</label><label class="expand" for="c-41186809">[8 more]</label></div><br/><div class="children"><div class="content">That would be amazing! More businesses need a costs-plus gun held to their head.</div><br/><div id="41187727" class="c"><input type="checkbox" id="c-41187727" checked=""/><div class="controls bullet"><span class="by">refurb</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186809">parent</a><span>|</span><a href="#41186893">next</a><span>|</span><label class="collapse" for="c-41187727">[-]</label><label class="expand" for="c-41187727">[3 more]</label></div><br/><div class="children"><div class="content">Would you be willing to work for a cost-plus salary?<p>Figure out what a middle-class lifestyle costs and pay you 10% more?</div><br/><div id="41189071" class="c"><input type="checkbox" id="c-41189071" checked=""/><div class="controls bullet"><span class="by">amrocha</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41187727">parent</a><span>|</span><a href="#41186893">next</a><span>|</span><label class="collapse" for="c-41189071">[-]</label><label class="expand" for="c-41189071">[2 more]</label></div><br/><div class="children"><div class="content">Youâre saying this ironically but yes, I would. If there was an accepted living standard and every job paid according to that that would be amazing.</div><br/><div id="41189172" class="c"><input type="checkbox" id="c-41189172" checked=""/><div class="controls bullet"><span class="by">refurb</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41189071">parent</a><span>|</span><a href="#41186893">next</a><span>|</span><label class="collapse" for="c-41189172">[-]</label><label class="expand" for="c-41189172">[1 more]</label></div><br/><div class="children"><div class="content">That seems very anti-worker.</div><br/></div></div></div></div></div></div><div id="41186893" class="c"><input type="checkbox" id="c-41186893" checked=""/><div class="controls bullet"><span class="by">renewiltord</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186809">parent</a><span>|</span><a href="#41187727">prev</a><span>|</span><a href="#41186948">next</a><span>|</span><label class="collapse" for="c-41186893">[-]</label><label class="expand" for="c-41186893">[4 more]</label></div><br/><div class="children"><div class="content">It&#x27;s true. Harvard education costs $300k, so that engineer&#x27;s lifetime earnings can be $300k plus some small margin so that he does not price gouge. Community college engineer can be paid $2k+small margin.</div><br/><div id="41187143" class="c"><input type="checkbox" id="c-41187143" checked=""/><div class="controls bullet"><span class="by">pdntspa</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186893">parent</a><span>|</span><a href="#41186948">next</a><span>|</span><label class="collapse" for="c-41187143">[-]</label><label class="expand" for="c-41187143">[3 more]</label></div><br/><div class="children"><div class="content">Businesses are not people (despite what the law tries to make you think), and people should not be bound by the same limits as businesses.</div><br/><div id="41187455" class="c"><input type="checkbox" id="c-41187455" checked=""/><div class="controls bullet"><span class="by">renewiltord</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41187143">parent</a><span>|</span><a href="#41186948">next</a><span>|</span><label class="collapse" for="c-41187455">[-]</label><label class="expand" for="c-41187455">[2 more]</label></div><br/><div class="children"><div class="content">I see. So all software engineers can charge what they want until the moment they join another software engineer. The moment the two of them work together on a shared enterprise, their margin must be capped.<p>As an employer, hiring single-person LLCs provides such a strong advantage in this universe over hiring employees. The former can&#x27;t charge you more than a small percentage. The latter can charge as much as they want. I suppose we would all be like Uber drivers.</div><br/><div id="41188077" class="c"><input type="checkbox" id="c-41188077" checked=""/><div class="controls bullet"><span class="by">pdntspa</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41187455">parent</a><span>|</span><a href="#41186948">next</a><span>|</span><label class="collapse" for="c-41188077">[-]</label><label class="expand" for="c-41188077">[1 more]</label></div><br/><div class="children"><div class="content">Honestly, 10% above costs would put a lot of people far more into the black than they currently are, because you are failing to account for ongoing expenses which raises said cap by a lot. To say nothing that most folks are struggling to make rent and buy food; I think they would like such a deal.</div><br/></div></div></div></div></div></div></div></div></div></div><div id="41186948" class="c"><input type="checkbox" id="c-41186948" checked=""/><div class="controls bullet"><span class="by">malfist</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185928">parent</a><span>|</span><a href="#41186809">prev</a><span>|</span><a href="#41185899">next</a><span>|</span><label class="collapse" for="c-41186948">[-]</label><label class="expand" for="c-41186948">[1 more]</label></div><br/><div class="children"><div class="content">No one is suggesting it should be billed at only the cost of manufacturing. Recouping expenses incurred during R&amp;D are perfectly reasonable.<p>If you poked at the data a bit, you might find it interesting to learn that drug companies spend more money on advertising than R&amp;D</div><br/></div></div></div></div><div id="41185899" class="c"><input type="checkbox" id="c-41185899" checked=""/><div class="controls bullet"><span class="by">Analemma_</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185814">parent</a><span>|</span><a href="#41185928">prev</a><span>|</span><a href="#41187706">next</a><span>|</span><label class="collapse" for="c-41185899">[-]</label><label class="expand" for="c-41185899">[23 more]</label></div><br/><div class="children"><div class="content">I&#x27;m no fan of pharma industry but there&#x27;s an unfounded and troubling assumption embedded in this comment: that any drug price over cost-to-manufacture can only be extortion. How do people recoup R&amp;D costs (which are the vast majority of costs in getting a new drug onto the market)?</div><br/><div id="41186003" class="c"><input type="checkbox" id="c-41186003" checked=""/><div class="controls bullet"><span class="by">asveikau</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185899">parent</a><span>|</span><a href="#41186308">next</a><span>|</span><label class="collapse" for="c-41186003">[-]</label><label class="expand" for="c-41186003">[10 more]</label></div><br/><div class="children"><div class="content">Doesn&#x27;t the government also fund a lot of pharma R&amp;D?<p>Here&#x27;s a 2019 article that came up in a Google search: Taxpayers funded this HIV research. The government patented it. Now a company profits
<a href="https:&#x2F;&#x2F;www.latimes.com&#x2F;business&#x2F;la-fi-gilead-sciences-truvada-hiv-prep-20190327-story.html" rel="nofollow">https:&#x2F;&#x2F;www.latimes.com&#x2F;business&#x2F;la-fi-gilead-sciences-truva...</a></div><br/><div id="41188184" class="c"><input type="checkbox" id="c-41188184" checked=""/><div class="controls bullet"><span class="by">pfisherman</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186003">parent</a><span>|</span><a href="#41186149">next</a><span>|</span><label class="collapse" for="c-41188184">[-]</label><label class="expand" for="c-41188184">[1 more]</label></div><br/><div class="children"><div class="content">The government funds a lot of early stage preclinical research. These are the inexpensive stages of the pipeline.<p>As soon as you move into humans you can add another 2 or 3 zeros to your burn rate.<p>It is not politically feasible for the public sector to fund later stages.  The numbers are just too big. Just think of the campaign ads that would run around $200M late stage failure funded by the government.<p>The reason why mega giant pharma companies exist is because they make enough money and are capitalized enough to withstand multiple $100M failures without going belly up.</div><br/></div></div><div id="41186149" class="c"><input type="checkbox" id="c-41186149" checked=""/><div class="controls bullet"><span class="by">tptacek</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186003">parent</a><span>|</span><a href="#41188184">prev</a><span>|</span><a href="#41186308">next</a><span>|</span><label class="collapse" for="c-41186149">[-]</label><label class="expand" for="c-41186149">[8 more]</label></div><br/><div class="children"><div class="content">Taxpayers fund all sorts of stuff that is ultimately commercialized!</div><br/><div id="41186500" class="c"><input type="checkbox" id="c-41186500" checked=""/><div class="controls bullet"><span class="by">asveikau</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186149">parent</a><span>|</span><a href="#41186380">next</a><span>|</span><label class="collapse" for="c-41186500">[-]</label><label class="expand" for="c-41186500">[6 more]</label></div><br/><div class="children"><div class="content">So that&#x27;s an argument that the government and the public should get a return on that investment, or profits should be constrained.<p>Or an argument against exclusive rights being in private hands.</div><br/><div id="41186778" class="c"><input type="checkbox" id="c-41186778" checked=""/><div class="controls bullet"><span class="by">ToValueFunfetti</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186500">parent</a><span>|</span><a href="#41186571">next</a><span>|</span><label class="collapse" for="c-41186778">[-]</label><label class="expand" for="c-41186778">[4 more]</label></div><br/><div class="children"><div class="content">The public gets access to a life-saving drug that otherwise would not exist, which is exactly what the government is paying for. You can reasonably argue they they should get more, but arguing that they should get some ROI is moot; they&#x27;re already getting a tremendous ROI</div><br/><div id="41188022" class="c"><input type="checkbox" id="c-41188022" checked=""/><div class="controls bullet"><span class="by">BigJono</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186778">parent</a><span>|</span><a href="#41186874">next</a><span>|</span><label class="collapse" for="c-41188022">[-]</label><label class="expand" for="c-41188022">[1 more]</label></div><br/><div class="children"><div class="content">What do you mean by &quot;gets access&quot;?<p>If the R&amp;D cost (including amortised failures and whatever) for some hypothetical drug is $1B and the manufacturing cost is $100M for 100M doses. The drug should cost about $11 + a reasonable markup in a fully private system.<p>If the R&amp;D costs are fully funded by taxpayers, it should cost $1 + a reasonable markup.<p>The public doesn&#x27;t &quot;get&quot; anything if it still costs $11 (+markup) and a company is allowed to take a 1000% profit margin because they&#x27;re only risking the $100M for the manufacturing.</div><br/></div></div><div id="41186874" class="c"><input type="checkbox" id="c-41186874" checked=""/><div class="controls bullet"><span class="by">asveikau</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186778">parent</a><span>|</span><a href="#41188022">prev</a><span>|</span><a href="#41187048">next</a><span>|</span><label class="collapse" for="c-41186874">[-]</label><label class="expand" for="c-41186874">[1 more]</label></div><br/><div class="children"><div class="content">The public gets the privilege to be price gouged for stuff their taxes paid for. Doesn&#x27;t sound like a good deal. Many will not have access at higher costs. Price gouging restricts access.</div><br/></div></div><div id="41187048" class="c"><input type="checkbox" id="c-41187048" checked=""/><div class="controls bullet"><span class="by">heavyset_go</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186778">parent</a><span>|</span><a href="#41186874">prev</a><span>|</span><a href="#41186571">next</a><span>|</span><label class="collapse" for="c-41187048">[-]</label><label class="expand" for="c-41187048">[1 more]</label></div><br/><div class="children"><div class="content">&gt; <i>The public gets access</i><p>Just a reminder that on-patent Truvada cost $4,500 for a 30 day supply of a drug that needs to be taken every day.</div><br/></div></div></div></div><div id="41186571" class="c"><input type="checkbox" id="c-41186571" checked=""/><div class="controls bullet"><span class="by">sroussey</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186500">parent</a><span>|</span><a href="#41186778">prev</a><span>|</span><a href="#41186380">next</a><span>|</span><label class="collapse" for="c-41186571">[-]</label><label class="expand" for="c-41186571">[1 more]</label></div><br/><div class="children"><div class="content">Universities certainly do. IP transfer is big business.<p>Subsidies for oil, not so much.</div><br/></div></div></div></div><div id="41186380" class="c"><input type="checkbox" id="c-41186380" checked=""/><div class="controls bullet"><span class="by">kiba</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186149">parent</a><span>|</span><a href="#41186500">prev</a><span>|</span><a href="#41186308">next</a><span>|</span><label class="collapse" for="c-41186380">[-]</label><label class="expand" for="c-41186380">[1 more]</label></div><br/><div class="children"><div class="content">The outcome for taxpayer ROI should be about the benefit to the public at large regardless of who commercialized it. Commercialization should eventually lead to better and cheaper version of the technology, which increases benefit to the public.<p>Of course, the people who worked to commercialize it deserve pay for their work, so the question is exactly how much.</div><br/></div></div></div></div></div></div><div id="41186308" class="c"><input type="checkbox" id="c-41186308" checked=""/><div class="controls bullet"><span class="by">WalterSear</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185899">parent</a><span>|</span><a href="#41186003">prev</a><span>|</span><a href="#41186566">next</a><span>|</span><label class="collapse" for="c-41186308">[-]</label><label class="expand" for="c-41186308">[2 more]</label></div><br/><div class="children"><div class="content">&gt; the vast majority of costs in getting a new drug onto the market<p>Debatable.<p>&gt; according to these firms&#x27; annual reports, 16 percent of revenues was taken as profit, and â¢ 31 percent went for marketing and administration. That&#x27;s nearly three times as much as their R&amp;D spending.<p><a href="https:&#x2F;&#x2F;www.bu.edu&#x2F;sph&#x2F;files&#x2F;2015&#x2F;05&#x2F;Pharmaceutical-Marketing-and-Research-Spending-APHA-21-Oct-01.pdf" rel="nofollow">https:&#x2F;&#x2F;www.bu.edu&#x2F;sph&#x2F;files&#x2F;2015&#x2F;05&#x2F;Pharmaceutical-Marketin...</a></div><br/><div id="41188272" class="c"><input type="checkbox" id="c-41188272" checked=""/><div class="controls bullet"><span class="by">AuryGlenz</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186308">parent</a><span>|</span><a href="#41186566">next</a><span>|</span><label class="collapse" for="c-41188272">[-]</label><label class="expand" for="c-41188272">[1 more]</label></div><br/><div class="children"><div class="content">Marketing gets them more money, which then increases the amount they can put into R&amp;D. They arenât spending on marketing without expecting a return.</div><br/></div></div></div></div><div id="41186566" class="c"><input type="checkbox" id="c-41186566" checked=""/><div class="controls bullet"><span class="by">smt88</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185899">parent</a><span>|</span><a href="#41186308">prev</a><span>|</span><a href="#41188476">next</a><span>|</span><label class="collapse" for="c-41186566">[-]</label><label class="expand" for="c-41186566">[1 more]</label></div><br/><div class="children"><div class="content">I think it&#x27;s perfectly fine to assume that it&#x27;s a form of extortion to profit from life-saving products, which is why some people agree that pharmaceuticals shouldn&#x27;t be a for-profit industry at all.</div><br/></div></div><div id="41188476" class="c"><input type="checkbox" id="c-41188476" checked=""/><div class="controls bullet"><span class="by">mock-possum</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185899">parent</a><span>|</span><a href="#41186566">prev</a><span>|</span><a href="#41186044">next</a><span>|</span><label class="collapse" for="c-41188476">[-]</label><label class="expand" for="c-41188476">[1 more]</label></div><br/><div class="children"><div class="content">Itâs life-saving medication. It should be freely available to everyone, period.<p>If weâre not willing to question the degree to which big pharma ought to profit off of controlling access to scientific miracles, the least we could do is use taxes to subsidize the cost - âI canât afford itâ should not be a reason to not be on PrEP.<p>Anyone should be able to walk into a CVS and walk out with 2-1-1 dose, as easily as theyâd pick up the morning after pill, or a bottle of aspirin.</div><br/></div></div><div id="41186044" class="c"><input type="checkbox" id="c-41186044" checked=""/><div class="controls bullet"><span class="by">chimeracoder</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185899">parent</a><span>|</span><a href="#41188476">prev</a><span>|</span><a href="#41187333">next</a><span>|</span><label class="collapse" for="c-41186044">[-]</label><label class="expand" for="c-41186044">[7 more]</label></div><br/><div class="children"><div class="content">Gilead&#x27;s R&amp;D costs for Truvada as PrEP were literally almost zero. They paid none of the costs for actually conducting the trials.<p>Their only contribution was that they donated the actual pills used in the trials - in other words, the unit price of 30 pills per person for the duration of the trial.<p>PrEP has been pure, risk-free profit for Gilead.</div><br/><div id="41186337" class="c"><input type="checkbox" id="c-41186337" checked=""/><div class="controls bullet"><span class="by">jayshua</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186044">parent</a><span>|</span><a href="#41186157">next</a><span>|</span><label class="collapse" for="c-41186337">[-]</label><label class="expand" for="c-41186337">[4 more]</label></div><br/><div class="children"><div class="content">Gilead claims that is false and that they spent 1.1 billion on developing Truvada.
 <a href="https:&#x2F;&#x2F;www.gilead.com&#x2F;news-and-press&#x2F;company-statements&#x2F;gilead--sciences--statement--on--inaccurate--reporting--on--truvada" rel="nofollow">https:&#x2F;&#x2F;www.gilead.com&#x2F;news-and-press&#x2F;company-statements&#x2F;gil...</a></div><br/><div id="41186754" class="c"><input type="checkbox" id="c-41186754" checked=""/><div class="controls bullet"><span class="by">comex</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186337">parent</a><span>|</span><a href="#41186801">next</a><span>|</span><label class="collapse" for="c-41186754">[-]</label><label class="expand" for="c-41186754">[2 more]</label></div><br/><div class="children"><div class="content">The $1.1 billion figure is for Truvada total, not for PrEP specifically.  Itâs perhaps notable that Gilead chose not to break that down, given that the original claim they were responding to <i>was</i> about PrEP specifically.</div><br/><div id="41186825" class="c"><input type="checkbox" id="c-41186825" checked=""/><div class="controls bullet"><span class="by">chimeracoder</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186754">parent</a><span>|</span><a href="#41186801">next</a><span>|</span><label class="collapse" for="c-41186825">[-]</label><label class="expand" for="c-41186825">[1 more]</label></div><br/><div class="children"><div class="content">&gt; The $1.1 billion figure is for Truvada total, not for PrEP specifically. Itâs perhaps notable that Gilead chose not to break that down, given that the original claim they were responding to was about PrEP specifically.<p>And even then it&#x27;s a dishonest claim. Half of that $1.1 billion is the amount of money they paid to acquire another biotech company in a firesale. It&#x27;s beyond disingenuous for them to claim all of that towards the amount they spent developing Truvada, since they received way more assets in that sale than just the patent for one drug.</div><br/></div></div></div></div><div id="41186801" class="c"><input type="checkbox" id="c-41186801" checked=""/><div class="controls bullet"><span class="by">chimeracoder</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186337">parent</a><span>|</span><a href="#41186754">prev</a><span>|</span><a href="#41186157">next</a><span>|</span><label class="collapse" for="c-41186801">[-]</label><label class="expand" for="c-41186801">[1 more]</label></div><br/><div class="children"><div class="content">&gt; Gilead claims that is false and that they spent 1.1 billion on developing Truvada. <a href="https:&#x2F;&#x2F;www.gilead.com&#x2F;news-and-press&#x2F;company-statements&#x2F;gil" rel="nofollow">https:&#x2F;&#x2F;www.gilead.com&#x2F;news-and-press&#x2F;company-statements&#x2F;gil</a>...<p>You are quoting a corporate press release that was written in response to an editorial criticizing Gilead, which was based on my colleagues&#x27; work.<p>This is a great example of how easy it is to fall for propaganda, because not a single thing in your link refutes what I said! They spent money developing Truvada <i>as a treatment for HIV</i>, then made that money back in record profits for nearly a decade. Only <i>then</i> did clinical trials for PrEP begin, and for those, Gilead donated only the production costs of Truvada (which are minimal). They did not spend any money in actually conducting the trials - which, as pharmaceutical companies are generally very quick to point out - is where most of the costs of bringing a drug to market are.<p>Gilead is claiming that, when it spent half a billion dollars to acquire a biotech company that went bankrupt, 100% of the money in that transaction should as &quot;R&amp;D related to Truvada&quot;. This is preposterous. Neither the SEC nor the IRS would endorse that accounting, which is why you&#x27;re seeing it in a press release and not their 10-K.<p>That&#x27;s a ridiculous claim even when you&#x27;re talking about the development of Truvada, but that&#x27;s not even the question at hand. The actual topic is how much was paid for the development of PrEP, which came nearly a decade later, and for which Gilead paid nothing but the per-unit costs of production.</div><br/></div></div></div></div><div id="41186157" class="c"><input type="checkbox" id="c-41186157" checked=""/><div class="controls bullet"><span class="by">yieldcrv</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41186044">parent</a><span>|</span><a href="#41186337">prev</a><span>|</span><a href="#41186158">next</a><span>|</span><label class="collapse" for="c-41186157">[-]</label><label class="expand" for="c-41186157">[1 more]</label></div><br/><div class="children"><div class="content">Although this is a discussion about costs<p>I just want to point out that the government has assumed the role of telling everyone how to take risks for its economy, and literally all you have to do is do that, successfully, and it will privilege your rewards by reducing risk on profits or reducing taxes<p>This is not controversial when you look at the stateâs role in these outcomes</div><br/></div></div></div></div><div id="41187333" class="c"><input type="checkbox" id="c-41187333" checked=""/><div class="controls bullet"><span class="by">scotty79</span><span>|</span><a href="#41185536">root</a><span>|</span><a href="#41185899">parent</a><span>|</span><a href="#41186044">prev</a><span>|</span><a href="#41187706">next</a><span>|</span><label class="collapse" for="c-41187333">[-]</label><label class="expand" for="c-41187333">[1 more]</label></div><br/><div class="children"><div class="content">To find the correct pricing you just check how much shareholders make. If they get unreasonably high return on their investment that means the company is overcharging.<p>Tax shareholders on their gains and rebate customers if the company doesn&#x27;t adjust the price.</div><br/></div></div></div></div></div></div><div id="41187706" class="c"><input type="checkbox" id="c-41187706" checked=""/><div class="controls bullet"><span class="by">refurb</span><span>|</span><a href="#41185536">parent</a><span>|</span><a href="#41185814">prev</a><span>|</span><a href="#41188319">next</a><span>|</span><label class="collapse" for="c-41187706">[-]</label><label class="expand" for="c-41187706">[1 more]</label></div><br/><div class="children"><div class="content">&gt; A drug you take 2 times a year could be much cheaper than one you take 365 times a year, and that&#x27;s a big deal.<p>Dosing doesn&#x27;t impact price.  Pharmaceuticals aren&#x27;t based on &quot;cost-plus&quot; pricing.</div><br/></div></div><div id="41188319" class="c"><input type="checkbox" id="c-41188319" checked=""/><div class="controls bullet"><span class="by">hadlock</span><span>|</span><a href="#41185536">parent</a><span>|</span><a href="#41187706">prev</a><span>|</span><a href="#41185115">next</a><span>|</span><label class="collapse" for="c-41188319">[-]</label><label class="expand" for="c-41188319">[1 more]</label></div><br/><div class="children"><div class="content">Why would they give up the profit? What&#x27;s your rationale here?<p>Cure = $X<p>If the treatment is daily then it&#x27;s $X&#x2F;365 if it&#x27;s monthly the price is $X&#x2F;12 if it&#x27;s twice a year it&#x27;s $X&#x2F;2<p>Imagine being an exec at that company and being like &quot;let&#x27;s give up 50&#x2F;52 of our profit because it&#x27;s more convenient for the patient&quot;? How many hours would it take between giving that speech and getting fired, do you think?</div><br/></div></div></div></div><div id="41185115" class="c"><input type="checkbox" id="c-41185115" checked=""/><div class="controls bullet"><span class="by">hodder</span><span>|</span><a href="#41185536">prev</a><span>|</span><a href="#41185040">next</a><span>|</span><label class="collapse" for="c-41185115">[-]</label><label class="expand" for="c-41185115">[23 more]</label></div><br/><div class="children"><div class="content">Please forgive my lack of understanding. This appears to be a great achievement. 
Is there any risk that a Lenacapavir resistant strain would rise up in many years as a result of treating a large portion of the global at risk population (estimated to be 60m people receiving the injection to materially lower global HIV rates)?<p>Sort of like how antibiotic resistant bacteria rates seems to evolve out of the use of antibiotics? Or is that not a thing and Im just clueless?</div><br/><div id="41185285" class="c"><input type="checkbox" id="c-41185285" checked=""/><div class="controls bullet"><span class="by">4fterd4rk</span><span>|</span><a href="#41185115">parent</a><span>|</span><a href="#41185856">next</a><span>|</span><label class="collapse" for="c-41185285">[-]</label><label class="expand" for="c-41185285">[12 more]</label></div><br/><div class="children"><div class="content">From another source:<p>&quot;The medication works in two ways: First, it interrupts viral replication by preventing HIV from reaching the nucleus of an infected cell, which then blocks reproduction.<p>The second mechanism is for cases in which integration of the HIV genome has already occurred. In this instance, lenacapavir interferes with production of viral progeny, âmaking them defective so that they are not able to infect other cells.â Therefore, it works in both early and late stages of the HIV life cycle to disrupt replication.&quot;<p>Since the drug works in two ways, it would be difficult for the virus to adapt. Similarly to how the current commonly prescribed PrEP regimen (Descovy or Truvada) is two different drugs in one pill and has not lead to any significant rise in resistance.</div><br/><div id="41185697" class="c"><input type="checkbox" id="c-41185697" checked=""/><div class="controls bullet"><span class="by">gibolt</span><span>|</span><a href="#41185115">root</a><span>|</span><a href="#41185285">parent</a><span>|</span><a href="#41185856">next</a><span>|</span><label class="collapse" for="c-41185697">[-]</label><label class="expand" for="c-41185697">[11 more]</label></div><br/><div class="children"><div class="content">Difficult doesn&#x27;t mean impossible. Trillions and trillions of chances for mutations to happen may lead to resistance over some period of time.<p>Hopefully not, but evolution is a powerful beast.</div><br/><div id="41189443" class="c"><input type="checkbox" id="c-41189443" checked=""/><div class="controls bullet"><span class="by">Moldoteck</span><span>|</span><a href="#41185115">root</a><span>|</span><a href="#41185697">parent</a><span>|</span><a href="#41185753">next</a><span>|</span><label class="collapse" for="c-41189443">[-]</label><label class="expand" for="c-41189443">[1 more]</label></div><br/><div class="children"><div class="content">this could happen, but hiv isn&#x27;t contagious like the flu so even if there&#x27;ll be an individual with such a strain - how likely it&#x27;ll pass to others?
Also, this drug limits replication, meaning there&#x27;ll be less and less mutations over time compared to a fully spread virus</div><br/></div></div><div id="41185753" class="c"><input type="checkbox" id="c-41185753" checked=""/><div class="controls bullet"><span class="by">Vecr</span><span>|</span><a href="#41185115">root</a><span>|</span><a href="#41185697">parent</a><span>|</span><a href="#41189443">prev</a><span>|</span><a href="#41185856">next</a><span>|</span><label class="collapse" for="c-41185753">[-]</label><label class="expand" for="c-41185753">[9 more]</label></div><br/><div class="children"><div class="content">Yes that is correct, it&#x27;s pretty easy to create escape variants in the lab. I don&#x27;t think people should be doing it with virus like HIV and SARS, but they do.</div><br/><div id="41186150" class="c"><input type="checkbox" id="c-41186150" checked=""/><div class="controls bullet"><span class="by">ljsprague</span><span>|</span><a href="#41185115">root</a><span>|</span><a href="#41185753">parent</a><span>|</span><a href="#41185856">next</a><span>|</span><label class="collapse" for="c-41186150">[-]</label><label class="expand" for="c-41186150">[8 more]</label></div><br/><div class="children"><div class="content">What about with coronaviruses?</div><br/><div id="41186294" class="c"><input type="checkbox" id="c-41186294" checked=""/><div class="controls bullet"><span class="by">nkozyra</span><span>|</span><a href="#41185115">root</a><span>|</span><a href="#41186150">parent</a><span>|</span><a href="#41186211">next</a><span>|</span><label class="collapse" for="c-41186294">[-]</label><label class="expand" for="c-41186294">[6 more]</label></div><br/><div class="children"><div class="content">Fair argument for doing it with highly mutative viruses like coronavirus and influenza, because it gives you a chance to prepare.</div><br/><div id="41186826" class="c"><input type="checkbox" id="c-41186826" checked=""/><div class="controls bullet"><span class="by">mkolodny</span><span>|</span><a href="#41185115">root</a><span>|</span><a href="#41186294">parent</a><span>|</span><a href="#41186211">next</a><span>|</span><label class="collapse" for="c-41186826">[-]</label><label class="expand" for="c-41186826">[5 more]</label></div><br/><div class="children"><div class="content">I&#x27;m surprised people are still making that argument even after the pandemic showed us the risk is nowhere near worth the reward. Regardless you need to create a vaccine for the discovered virus (which can take less than a week, as was the case with covid). And then you still need to go through months of human trials.<p>I was hoping we were done risking starting pandemics by purposefully creating new deadly viruses.</div><br/><div id="41189113" class="c"><input type="checkbox" id="c-41189113" checked=""/><div class="controls bullet"><span class="by">jjeaff</span><span>|</span><a href="#41185115">root</a><span>|</span><a href="#41186826">parent</a><span>|</span><a href="#41189110">next</a><span>|</span><label class="collapse" for="c-41189113">[-]</label><label class="expand" for="c-41189113">[1 more]</label></div><br/><div class="children"><div class="content">the jury is still out on whether COVID originated from a lab. it seems very possible, but there is still little evidence that proves it was created in a lab.</div><br/></div></div><div id="41189110" class="c"><input type="checkbox" id="c-41189110" checked=""/><div class="controls bullet"><span class="by">zelphirkalt</span><span>|</span><a href="#41185115">root</a><span>|</span><a href="#41186826">parent</a><span>|</span><a href="#41189113">prev</a><span>|</span><a href="#41188007">next</a><span>|</span><label class="collapse" for="c-41189110">[-]</label><label class="expand" for="c-41189110">[1 more]</label></div><br/><div class="children"><div class="content">Is this assuming, that Covid was lab made? Since I have not seen or read about proof of that theory, this comes across a bit like conspiracy theory.</div><br/></div></div><div id="41188007" class="c"><input type="checkbox" id="c-41188007" checked=""/><div class="controls bullet"><span class="by">HaZeust</span><span>|</span><a href="#41185115">root</a><span>|</span><a href="#41186826">parent</a><span>|</span><a href="#41189110">prev</a><span>|</span><a href="#41186211">next</a><span>|</span><label class="collapse" for="c-41188007">[-]</label><label class="expand" for="c-41188007">[2 more]</label></div><br/><div class="children"><div class="content">Can you please cite a source that shares that it took &quot;less than a week&quot; for the COVID vaccine to be developed after discovery?</div><br/><div id="41188167" class="c"><input type="checkbox" id="c-41188167" checked=""/><div class="controls bullet"><span class="by">mkolodny</span><span>|</span><a href="#41185115">root</a><span>|</span><a href="#41188007">parent</a><span>|</span><a href="#41186211">next</a><span>|</span><label class="collapse" for="c-41188167">[-]</label><label class="expand" for="c-41188167">[1 more]</label></div><br/><div class="children"><div class="content">âYou may be surprised to learn that of the trio of long-awaited coronavirus vaccines, the most promising, Modernaâs mRNA-1273, which reported a 94.5 percent efficacy rate on November 16, had been designed by January 13. This was just two days after the genetic sequence had been made publicâ<p><a href="https:&#x2F;&#x2F;nymag.com&#x2F;intelligencer&#x2F;2020&#x2F;12&#x2F;moderna-covid-19-vaccine-design.html" rel="nofollow">https:&#x2F;&#x2F;nymag.com&#x2F;intelligencer&#x2F;2020&#x2F;12&#x2F;moderna-covid-19-vac...</a></div><br/></div></div></div></div></div></div></div></div><div id="41186211" class="c"><input type="checkbox" id="c-41186211" checked=""/><div class="controls bullet"><span class="by">fwip</span><span>|</span><a href="#41185115">root</a><span>|</span><a href="#41186150">parent</a><span>|</span><a href="#41186294">prev</a><span>|</span><a href="#41185856">next</a><span>|</span><label class="collapse" for="c-41186211">[-]</label><label class="expand" for="c-41186211">[1 more]</label></div><br/><div class="children"><div class="content">SARS was caused by a coronavirus.</div><br/></div></div></div></div></div></div></div></div></div></div><div id="41185856" class="c"><input type="checkbox" id="c-41185856" checked=""/><div class="controls bullet"><span class="by">argonaut</span><span>|</span><a href="#41185115">parent</a><span>|</span><a href="#41185285">prev</a><span>|</span><a href="#41185267">next</a><span>|</span><label class="collapse" for="c-41185856">[-]</label><label class="expand" for="c-41185856">[2 more]</label></div><br/><div class="children"><div class="content">HIV drug resistance is a real issue, not sure why other comments are dismissing the risk of resistance. The risk of resistance is why HIV positive individuals take a cocktail of drugs, and why PrEP (Truvada or Descovy) requires regular HIV testing (because if you end up positive you need to upgraded to a cocktail of drugs).</div><br/><div id="41186096" class="c"><input type="checkbox" id="c-41186096" checked=""/><div class="controls bullet"><span class="by">ProfessorLayton</span><span>|</span><a href="#41185115">root</a><span>|</span><a href="#41185856">parent</a><span>|</span><a href="#41185267">next</a><span>|</span><label class="collapse" for="c-41186096">[-]</label><label class="expand" for="c-41186096">[1 more]</label></div><br/><div class="children"><div class="content">PrEP is incredibly effective, and even better than condoms at preventing HIV. There&#x27;s various reasons it requires regular testing:<p>- While very effective, it requires people to actually take it consistently, which is why the injectable form is better for some than the pill.<p>- PrEP is not without side effects for a small portion of its users. In some cases it can cause bone density loss, or kidney damage. These tests are intended to catch any issues before they cause any permanent damage.<p>- Since people are coming in to get tested for the aforementioned issues, they also run a full STI panel. This is great and it means those on PrEP (And those managing HIV) are tested more frequently than the general population, and are less likely to transmit an STI than those who don&#x27;t come in for regular testing.</div><br/></div></div></div></div><div id="41185287" class="c"><input type="checkbox" id="c-41185287" checked=""/><div class="controls bullet"><span class="by">chimeracoder</span><span>|</span><a href="#41185115">parent</a><span>|</span><a href="#41185267">prev</a><span>|</span><a href="#41186101">next</a><span>|</span><label class="collapse" for="c-41185287">[-]</label><label class="expand" for="c-41185287">[1 more]</label></div><br/><div class="children"><div class="content">&gt; Please forgive my lack of understanding. This appears to be a great achievement. Is there any risk that a Lenacapavir resistant strain would rise up in many years as a result of treating a large portion of the global at risk population (estimated to be 60m people receiving the injection to materially lower global HIV rates)?<p>Not really. This same principle has been used for over a decade. The only difference here is that the previous version of injectables needed to be administered every two months, whereas this can be done every six months.</div><br/></div></div><div id="41186101" class="c"><input type="checkbox" id="c-41186101" checked=""/><div class="controls bullet"><span class="by">gwbas1c</span><span>|</span><a href="#41185115">parent</a><span>|</span><a href="#41185287">prev</a><span>|</span><a href="#41185040">next</a><span>|</span><label class="collapse" for="c-41186101">[-]</label><label class="expand" for="c-41186101">[6 more]</label></div><br/><div class="children"><div class="content">(Joke) I&#x27;m still waiting for bacteria to evolve a resistance to boiling!<p>(Seriousness) Different infectious agents can &#x2F; can not evolve around their vaccines. We don&#x27;t get yearly polio shots, we do get yearly covid&#x2F;flu shots.<p>(Speculation) It&#x27;s probably too early to tell if there&#x27;s a way for HIV to evolve around this, but it might have something to do with how effective we are at killing HIV in our population to begin with.</div><br/><div id="41186290" class="c"><input type="checkbox" id="c-41186290" checked=""/><div class="controls bullet"><span class="by">foobiekr</span><span>|</span><a href="#41185115">root</a><span>|</span><a href="#41186101">parent</a><span>|</span><a href="#41186121">next</a><span>|</span><label class="collapse" for="c-41186290">[-]</label><label class="expand" for="c-41186290">[1 more]</label></div><br/><div class="children"><div class="content">I know it was a joke but lots of bacteria can survive simple boiling as endospores.</div><br/></div></div><div id="41186121" class="c"><input type="checkbox" id="c-41186121" checked=""/><div class="controls bullet"><span class="by">shrimp_emoji</span><span>|</span><a href="#41185115">root</a><span>|</span><a href="#41186101">parent</a><span>|</span><a href="#41186290">prev</a><span>|</span><a href="#41186145">next</a><span>|</span><label class="collapse" for="c-41186121">[-]</label><label class="expand" for="c-41186121">[1 more]</label></div><br/><div class="children"><div class="content">Are you an elcor?</div><br/></div></div><div id="41186145" class="c"><input type="checkbox" id="c-41186145" checked=""/><div class="controls bullet"><span class="by">Vecr</span><span>|</span><a href="#41185115">root</a><span>|</span><a href="#41186101">parent</a><span>|</span><a href="#41186121">prev</a><span>|</span><a href="#41185040">next</a><span>|</span><label class="collapse" for="c-41186145">[-]</label><label class="expand" for="c-41186145">[3 more]</label></div><br/><div class="children"><div class="content">Polio can and does mutate almost instantly around the vaccines, but since some of the vaccines are live polio anyway people don&#x27;t really care. &quot;Mutation&quot; is not really a word that matters, what matters is if a variant is causing problems.</div><br/><div id="41186305" class="c"><input type="checkbox" id="c-41186305" checked=""/><div class="controls bullet"><span class="by">foobiekr</span><span>|</span><a href="#41185115">root</a><span>|</span><a href="#41186145">parent</a><span>|</span><a href="#41185040">next</a><span>|</span><label class="collapse" for="c-41186305">[-]</label><label class="expand" for="c-41186305">[2 more]</label></div><br/><div class="children"><div class="content">On rare occasions the live vaccine actually reverts. Polio is an amazing story because the live vaccination campaign may have had collateral impact on the families of the vaccinated as they shed particles.</div><br/><div id="41186431" class="c"><input type="checkbox" id="c-41186431" checked=""/><div class="controls bullet"><span class="by">Vecr</span><span>|</span><a href="#41185115">root</a><span>|</span><a href="#41186305">parent</a><span>|</span><a href="#41185040">next</a><span>|</span><label class="collapse" for="c-41186431">[-]</label><label class="expand" for="c-41186431">[1 more]</label></div><br/><div class="children"><div class="content">Rare? It&#x27;s in almost everyone who gets the vaccine. I don&#x27;t have a direct citation, but I don&#x27;t think it&#x27;s generally doubted, though it&#x27;s not something that&#x27;s easy to do a direct controlled test on.</div><br/></div></div></div></div></div></div></div></div></div></div><div id="41185040" class="c"><input type="checkbox" id="c-41185040" checked=""/><div class="controls bullet"><span class="by">pfdietz</span><span>|</span><a href="#41185115">prev</a><span>|</span><a href="#41186680">next</a><span>|</span><label class="collapse" for="c-41185040">[-]</label><label class="expand" for="c-41185040">[2 more]</label></div><br/><div class="children"><div class="content">It&#x27;s a wonderful (if rare) event when a medical trial is stopped for efficacy.</div><br/></div></div><div id="41186680" class="c"><input type="checkbox" id="c-41186680" checked=""/><div class="controls bullet"><span class="by">mkl</span><span>|</span><a href="#41185040">prev</a><span>|</span><a href="#41188697">next</a><span>|</span><label class="collapse" for="c-41186680">[-]</label><label class="expand" for="c-41186680">[1 more]</label></div><br/><div class="children"><div class="content">Without mention of the number of study participants or risk, I was a bit suspicious, but it&#x27;s not a tiny sample size, and not a low-risk group.  From the paper:<p>&gt; Among 5338 participants who were initially HIV-negative, 55 incident HIV infections were observed: 0 infections among 2134 participants in the lenacapavir group<p>The infections in the control groups were in people taking other preventative medication, not nothing.</div><br/></div></div><div id="41188697" class="c"><input type="checkbox" id="c-41188697" checked=""/><div class="controls bullet"><span class="by">devonsolomon</span><span>|</span><a href="#41186680">prev</a><span>|</span><a href="#41184899">next</a><span>|</span><label class="collapse" for="c-41188697">[-]</label><label class="expand" for="c-41188697">[1 more]</label></div><br/><div class="children"><div class="content">30 years ago in South Africa there was fear about contracting HIV (and so inevitably dying) through the ear via public telephones (which is ridiculous and impossible). Doctors in trauma wards were terrified of contracting the disease. Huge amounts of stigma and misinformation, and little hope.<p>Itâs amazing that since then:
- A treated HIV diagnosis no longer necessarily changes your life expectancy.
- Your HIV negative partner or unborn child will not necessarily contract the disease, if treated.
- Treatment adherence requires just two visits a year.
- Doctors have a ready solution in the case of accidental potential transmission.
- I canât remember the last time I saw a public telephone.</div><br/></div></div><div id="41184899" class="c"><input type="checkbox" id="c-41184899" checked=""/><div class="controls bullet"><span class="by">sillysaurusx</span><span>|</span><a href="#41188697">prev</a><span>|</span><a href="#41186005">next</a><span>|</span><label class="collapse" for="c-41184899">[-]</label><label class="expand" for="c-41184899">[47 more]</label></div><br/><div class="children"><div class="content">In terms of protecting oneself, what are the actual steps? (E.g. if you&#x27;re HIV- but are participating in activities either directly with someone who is HIV+ or whose partner is HIV+.)<p>Do you schedule a doctor appointment and ask for something specific? And is there anything else to do, such as something over-the-counter?<p>There&#x27;s a dizzying array of terms to learn in this space. PrEP is apparently different from PEP, which I think is also unrelated to what this article is talking about. It&#x27;d be nice if someone put together a 2024 guide for what the latest preventative &#x2F; protection mechanisms are.</div><br/><div id="41184919" class="c"><input type="checkbox" id="c-41184919" checked=""/><div class="controls bullet"><span class="by">toomuchtodo</span><span>|</span><a href="#41184899">parent</a><span>|</span><a href="#41185381">next</a><span>|</span><label class="collapse" for="c-41184919">[-]</label><label class="expand" for="c-41184919">[27 more]</label></div><br/><div class="children"><div class="content">Assuming you do not currently have a viral load of HIV, you can meet with your provider, indicate that you are at risk, and request a prescription for PrEP [1] (Planned Parenthood can assist with sourcing if you don&#x27;t have a PCP or other stable medical providers). Longer term, it is likely there will be a shift to a twice yearly injectable (Gileadâs Lenacapavir) [2]. State of the art is an undetectable viral load due to antiviral treatment means you cannot transmit to others [3] [4] [5].<p>Not medical advice, educational purposes only. Seek a medical professional&#x27;s guidance for your personal circumstances.<p>[1] <a href="https:&#x2F;&#x2F;www.hiv.gov&#x2F;hiv-basics&#x2F;hiv-prevention&#x2F;using-hiv-medication-to-reduce-risk&#x2F;pre-exposure-prophylaxis" rel="nofollow">https:&#x2F;&#x2F;www.hiv.gov&#x2F;hiv-basics&#x2F;hiv-prevention&#x2F;using-hiv-medi...</a><p>[2] <a href="https:&#x2F;&#x2F;news.ycombinator.com&#x2F;item?id=40742163">https:&#x2F;&#x2F;news.ycombinator.com&#x2F;item?id=40742163</a><p>[3] <a href="https:&#x2F;&#x2F;www.hiv.gov&#x2F;hiv-basics&#x2F;staying-in-hiv-care&#x2F;hiv-treatment&#x2F;viral-suppression" rel="nofollow">https:&#x2F;&#x2F;www.hiv.gov&#x2F;hiv-basics&#x2F;staying-in-hiv-care&#x2F;hiv-treat...</a><p>[4] <a href="https:&#x2F;&#x2F;www.niaid.nih.gov&#x2F;diseases-conditions&#x2F;treatment-prevention" rel="nofollow">https:&#x2F;&#x2F;www.niaid.nih.gov&#x2F;diseases-conditions&#x2F;treatment-prev...</a><p>[5] <a href="https:&#x2F;&#x2F;www.hiv.gov&#x2F;blog&#x2F;science-validates-undetectable-untransmittable-hiv-prevention-message" rel="nofollow">https:&#x2F;&#x2F;www.hiv.gov&#x2F;blog&#x2F;science-validates-undetectable-untr...</a></div><br/><div id="41185125" class="c"><input type="checkbox" id="c-41185125" checked=""/><div class="controls bullet"><span class="by">ClarityJones</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41184919">parent</a><span>|</span><a href="#41185427">next</a><span>|</span><label class="collapse" for="c-41185125">[-]</label><label class="expand" for="c-41185125">[14 more]</label></div><br/><div class="children"><div class="content">From [5] <a href="https:&#x2F;&#x2F;www.hiv.gov&#x2F;blog&#x2F;science-validates-undetectable-untransmittable-hiv-prevention-message" rel="nofollow">https:&#x2F;&#x2F;www.hiv.gov&#x2F;blog&#x2F;science-validates-undetectable-untr...</a>:<p>&gt; Even when viral load is undetectable, ... may have detectable HIV genetic material in ... semen, but there is no scientific evidence that such material is associated with HIV transmission.<p>What? Isn&#x27;t that the primary transmission vector?</div><br/><div id="41186718" class="c"><input type="checkbox" id="c-41186718" checked=""/><div class="controls bullet"><span class="by">hyrix</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185125">parent</a><span>|</span><a href="#41185164">next</a><span>|</span><label class="collapse" for="c-41186718">[-]</label><label class="expand" for="c-41186718">[1 more]</label></div><br/><div class="children"><div class="content">Transmission has never been found when the number of copies of the HIV RNA are below 200 copies&#x2F;mL--the quantity of virus matters.<p>For context, the typical ejaculation from someone untreated contains between 10,000 and 1,000,000 copies&#x2F;mL. With treatment, the average is 1-10 copies&#x2F;mL.<p>Besides HPTN 052, there have been three other studies--PARTNER, PARTNER 2, and DISCOVER, of real-world (condomless) usage in mixed serotype couples<p><a href="https:&#x2F;&#x2F;www.idsociety.org&#x2F;science-speaks-blog&#x2F;2021&#x2F;u--u-the-evidence-is-in.-spreading-the-word-that-undetectable--untransmissable-is-the-next-crucial-step&#x2F;#&#x2F;+&#x2F;0&#x2F;publishedDate_na_dt&#x2F;desc&#x2F;" rel="nofollow">https:&#x2F;&#x2F;www.idsociety.org&#x2F;science-speaks-blog&#x2F;2021&#x2F;u--u-the-...</a><p><a href="https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC8942556&#x2F;" rel="nofollow">https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC8942556&#x2F;</a></div><br/></div></div><div id="41185164" class="c"><input type="checkbox" id="c-41185164" checked=""/><div class="controls bullet"><span class="by">toomuchtodo</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185125">parent</a><span>|</span><a href="#41186718">prev</a><span>|</span><a href="#41186210">next</a><span>|</span><label class="collapse" for="c-41185164">[-]</label><label class="expand" for="c-41185164">[2 more]</label></div><br/><div class="children"><div class="content">From that same link you cite:<p>&gt; Findings from the breakthrough NIH-funded HPTN 052 clinical trial, a decade-long study involving more than 1,600 heterosexual couples, offered clear-cut evidence that ART that consistently suppresses HIV also prevents sexual transmission of the virus. In 2011, the HPTN 052 investigators reported that starting ART when the immune system is relatively healthy, as opposed to delaying therapy until the immune system has been weakened by the virus, dramatically reduces the risk of sexually transmitting HIV. The protective effect of starting ART early was sustained over four additional years of follow-up. Importantly, when viral loads were measured, no HIV transmissions were observed when ART consistently, durably suppressed the virus in the partner living with HIV.<p>Wild speculation is that the genetic material you mention is inactivated and therefore unable to transmit the virus, but is still detectable. I am just an internet rando surfing the knowledge graph, but the science appears sound.<p><a href="https:&#x2F;&#x2F;www.nih.gov&#x2F;news-events&#x2F;news-releases&#x2F;hiv-control-through-treatment-durably-prevents-heterosexual-transmission-virus" rel="nofollow">https:&#x2F;&#x2F;www.nih.gov&#x2F;news-events&#x2F;news-releases&#x2F;hiv-control-th...</a><p><a href="https:&#x2F;&#x2F;web.archive.org&#x2F;web&#x2F;20150106032855&#x2F;http:&#x2F;&#x2F;www.niaid.nih.gov&#x2F;news&#x2F;newsreleases&#x2F;Archive&#x2F;2011&#x2F;Pages&#x2F;HPTN052Breakthrough.aspx" rel="nofollow">https:&#x2F;&#x2F;web.archive.org&#x2F;web&#x2F;20150106032855&#x2F;http:&#x2F;&#x2F;www.niaid....</a><p><a href="https:&#x2F;&#x2F;www.clinicaltrials.gov&#x2F;study&#x2F;NCT00074581" rel="nofollow">https:&#x2F;&#x2F;www.clinicaltrials.gov&#x2F;study&#x2F;NCT00074581</a></div><br/><div id="41186659" class="c"><input type="checkbox" id="c-41186659" checked=""/><div class="controls bullet"><span class="by">pstrateman</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185164">parent</a><span>|</span><a href="#41186210">next</a><span>|</span><label class="collapse" for="c-41186659">[-]</label><label class="expand" for="c-41186659">[1 more]</label></div><br/><div class="children"><div class="content">&gt;1,600 heterosexual couples<p>Is there a similar study of gay men who are not in a monogamous relationship?<p>Studying the group with the lowest transmission rate who could still transmit seems kind of dishonest.</div><br/></div></div></div></div><div id="41188373" class="c"><input type="checkbox" id="c-41188373" checked=""/><div class="controls bullet"><span class="by">dyauspitr</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185125">parent</a><span>|</span><a href="#41185221">prev</a><span>|</span><a href="#41185239">next</a><span>|</span><label class="collapse" for="c-41188373">[-]</label><label class="expand" for="c-41188373">[1 more]</label></div><br/><div class="children"><div class="content">From what Iâve read you need an absolute minimum of 10 virons for infection to happen.</div><br/></div></div><div id="41185239" class="c"><input type="checkbox" id="c-41185239" checked=""/><div class="controls bullet"><span class="by">Vecr</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185125">parent</a><span>|</span><a href="#41188373">prev</a><span>|</span><a href="#41185427">next</a><span>|</span><label class="collapse" for="c-41185239">[-]</label><label class="expand" for="c-41185239">[7 more]</label></div><br/><div class="children"><div class="content">I don&#x27;t buy U=U, I&#x27;ve not seen a proper impossibility proof re. provirus mutation. There&#x27;s probably infections drowned out against the background rate.</div><br/><div id="41185332" class="c"><input type="checkbox" id="c-41185332" checked=""/><div class="controls bullet"><span class="by">4fterd4rk</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185239">parent</a><span>|</span><a href="#41185427">next</a><span>|</span><label class="collapse" for="c-41185332">[-]</label><label class="expand" for="c-41185332">[6 more]</label></div><br/><div class="children"><div class="content">This has been extensively studied and you are wrong.<p><a href="https:&#x2F;&#x2F;www.thelancet.com&#x2F;journals&#x2F;lancet&#x2F;article&#x2F;PIIS0140-6736(19)30418-0&#x2F;fulltext" rel="nofollow">https:&#x2F;&#x2F;www.thelancet.com&#x2F;journals&#x2F;lancet&#x2F;article&#x2F;PIIS0140-6...</a></div><br/><div id="41185465" class="c"><input type="checkbox" id="c-41185465" checked=""/><div class="controls bullet"><span class="by">Vecr</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185332">parent</a><span>|</span><a href="#41185427">next</a><span>|</span><label class="collapse" for="c-41185465">[-]</label><label class="expand" for="c-41185465">[5 more]</label></div><br/><div class="children"><div class="content">I don&#x27;t think I am, in the provirus state you can think of it as essentially a DNA virus in an inert state, and if the DNA fragments the right way it would turn into something similar to a bare DNA vaccine. That design of vaccine essentially does not work, but they have an effect that is not literally zero. I think there&#x27;s enough holes in the layers of &quot;Swiss cheese&quot; that normally prevent this chain of events that U does not literally equal U.<p>Edit: right, I&#x27;m also assuming the possibility of provirus mutation before this chain of events, and I don&#x27;t think anyone can deny at least the mutation of HIV before it becomes a provirus.</div><br/><div id="41185626" class="c"><input type="checkbox" id="c-41185626" checked=""/><div class="controls bullet"><span class="by">theideaofcoffee</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185465">parent</a><span>|</span><a href="#41185427">next</a><span>|</span><label class="collapse" for="c-41185626">[-]</label><label class="expand" for="c-41185626">[4 more]</label></div><br/><div class="children"><div class="content">Are you a virologist, epidemiologist or other specialist with peer-reviewed research pointing in the direction opposite to the conclusions in the paper above? If so, you should publish your findings because that would be a huge refutation of current knowledge and would possibly help the epidemiology of transmission in the greater public.<p>Until then, I&#x27;ll take the word of public health practitioners who&#x27;ve been steeped in the field for their entire careers. Their work has been significant enough to be published in Lancet which is a pretty good signal to this layman (though with a bachelor&#x27;s of science in an unrelated scientific field, so no stranger to reading primary literature).</div><br/><div id="41185713" class="c"><input type="checkbox" id="c-41185713" checked=""/><div class="controls bullet"><span class="by">Vecr</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185626">parent</a><span>|</span><a href="#41186635">next</a><span>|</span><label class="collapse" for="c-41185713">[-]</label><label class="expand" for="c-41185713">[1 more]</label></div><br/><div class="children"><div class="content">I probably could write something, but HIV is an epidemiologist&#x27;s game at this point, and I honestly think the epidemiologists want to say HIV can&#x27;t transmit in ways that the Hepatitis B virus, a DNA virus, has clearly been demonstrated to transmit. If you press a virologist in private I&#x27;m not sure they&#x27;ll stick to &quot;can&#x27;t&quot;, especially after the COVID-19 virus mutation rate fiasco, and, though not a virus, the prion situation.<p>I think &quot;can&#x27;t&quot; deserves at least something physically (as in physics) unlikely, not something that&#x27;s been demonstrated in a DNA virus previously (and like I said, HIV in provirus form is not unlike a DNA virus).</div><br/></div></div><div id="41186635" class="c"><input type="checkbox" id="c-41186635" checked=""/><div class="controls bullet"><span class="by">serf</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185626">parent</a><span>|</span><a href="#41185713">prev</a><span>|</span><a href="#41185427">next</a><span>|</span><label class="collapse" for="c-41186635">[-]</label><label class="expand" for="c-41186635">[2 more]</label></div><br/><div class="children"><div class="content">&gt;Their work has been significant enough to be published in Lancet which is a pretty good signal to this layman (though with a bachelor&#x27;s of science in an unrelated scientific field, so no stranger to reading primary literature).<p>i&#x27;ve no opinion on the topic at hand, but I would urge you to find a plethora of signals to form your opinions.<p>The Lancet has been responsible for quite a few negative &#x27;public health&#x27; trends.<p>The Lancet is responsible, at least partially, for the whole &#x27;vaccines == autism&#x27; thing of Andrew Wakefield&#x27;s; and even ignoring that they have a history of poor review and retraction of work that ends up either being entirely wrong, or guilty of experimental misconduct.<p>In 1992 they published stuff that suggested a causal link between HIV infection and the oral polio vaccines.<p>In 1998 they published a (big tobacco funded) peper indicating that second hand smoke doesn&#x27;t have as much risk as earlier thought.<p>In 2000 they published a study that claimed that St Johns Wort was as effective an anti-depressant as conventional SSRIs and TCAs.<p>Just because something has become &#x27;prestigious&#x27; doesn&#x27;t mean it should be trusted wholeheartedly.</div><br/><div id="41189267" class="c"><input type="checkbox" id="c-41189267" checked=""/><div class="controls bullet"><span class="by">foldr</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41186635">parent</a><span>|</span><a href="#41185427">next</a><span>|</span><label class="collapse" for="c-41189267">[-]</label><label class="expand" for="c-41189267">[1 more]</label></div><br/><div class="children"><div class="content">This isn&#x27;t about the Lancet specifically. It&#x27;s about someone on the internet challenging the overwhelming medical consensus without providing a shred of evidence to support their claims. I can assure you that &#x27;people saying things on the internet&#x27; have a far worse record on medical matters than the Lancet, or the medical consensus more generally.</div><br/></div></div></div></div></div></div></div></div></div></div></div></div></div></div><div id="41185427" class="c"><input type="checkbox" id="c-41185427" checked=""/><div class="controls bullet"><span class="by">chimeracoder</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41184919">parent</a><span>|</span><a href="#41185125">prev</a><span>|</span><a href="#41185381">next</a><span>|</span><label class="collapse" for="c-41185427">[-]</label><label class="expand" for="c-41185427">[12 more]</label></div><br/><div class="children"><div class="content">&gt; Longer term, it is likely there will be a shift to a twice yearly injectable (Gileadâs Lenacapavir)<p>That&#x27;s debatable. Injectable PrEP has been around for years already (Lencapavir is not the first, just the most recent). Lencapavir has also not yet been tested on all at-risk groups, so unlike other forms of PrEP, it&#x27;s not a universal solution because it cannot be prescribed to all candidates.<p>Given the price, which is quite high <i>even with</i> the programs Gilead has said that it will issue to reduce the cost, it remains to be seen how widely-used Lencapavir becomes outside of specific markets.</div><br/><div id="41185591" class="c"><input type="checkbox" id="c-41185591" checked=""/><div class="controls bullet"><span class="by">nerdjon</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185427">parent</a><span>|</span><a href="#41185580">next</a><span>|</span><label class="collapse" for="c-41185591">[-]</label><label class="expand" for="c-41185591">[8 more]</label></div><br/><div class="children"><div class="content">The problem I think really comes down to there being a generic Truvada.<p>Insurance for a bit seemed fine with covering Descovy but it seems that is less of a case now since itâs so much more. I would expect the same with a shot like this.<p>However I would hope that the added benefit of not needing to worry about adhering to taking it every day could outweigh that financial cost for insurance.<p>I recently switched insurance companies and my new one covers Truvada completely, not even a copay. Itâs honestly kinda wild I pay more for my Adderall than I do prep. Obviously I donât know for sure but I have wondered if it is related to it being preventative and the potential alternative cost makes it smarter to remove any barriers.</div><br/><div id="41185913" class="c"><input type="checkbox" id="c-41185913" checked=""/><div class="controls bullet"><span class="by">argonaut</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185591">parent</a><span>|</span><a href="#41185864">next</a><span>|</span><label class="collapse" for="c-41185913">[-]</label><label class="expand" for="c-41185913">[6 more]</label></div><br/><div class="children"><div class="content">Almost all health insurance companies in the USA are required to fully cover PrEP, including Descovy. This doesn&#x27;t stop health insurance companies from trying to deny you, of course. You would have to appeal the denial all the way up to your state&#x27;s department for health insurance, but you would definitely win.<p>EDIT: I was mistaken, this only applies in California.</div><br/><div id="41185962" class="c"><input type="checkbox" id="c-41185962" checked=""/><div class="controls bullet"><span class="by">nerdjon</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185913">parent</a><span>|</span><a href="#41185981">next</a><span>|</span><label class="collapse" for="c-41185962">[-]</label><label class="expand" for="c-41185962">[2 more]</label></div><br/><div class="children"><div class="content">Thatâ¦ is good to know. I knew they were required but figured generic Truvada was the requirement.<p>Well kinda irrelevant. My previous insurance loved to deny things, itâs why my company changed.<p>I worked with my doctor, tried multiple times to get them to cover Descovy (I struggled with the larger pills, I finally just forced myself to get used to it) and was never successful. Just gave up.</div><br/><div id="41186016" class="c"><input type="checkbox" id="c-41186016" checked=""/><div class="controls bullet"><span class="by">chimeracoder</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185962">parent</a><span>|</span><a href="#41185981">next</a><span>|</span><label class="collapse" for="c-41186016">[-]</label><label class="expand" for="c-41186016">[1 more]</label></div><br/><div class="children"><div class="content">See my sibling comment. GP is half-correct. They are not required to cover Descovy specifically. Covering Truvada is sufficient to comply with the law (assuming they are also covering all associated labwork and outpatient visits, and not requiring you to pay anything out-of-pocket for any of those).</div><br/></div></div></div></div><div id="41185981" class="c"><input type="checkbox" id="c-41185981" checked=""/><div class="controls bullet"><span class="by">chimeracoder</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185913">parent</a><span>|</span><a href="#41185962">prev</a><span>|</span><a href="#41185864">next</a><span>|</span><label class="collapse" for="c-41185981">[-]</label><label class="expand" for="c-41185981">[3 more]</label></div><br/><div class="children"><div class="content">&gt; Almost all health insurance companies in the USA are required to fully cover PrEP, including Descovy. They aren&#x27;t even allowed to require that you try (generic) Truvada first before trying Descovy.<p>They are required to cover PrEP, but that doesn&#x27;t mean that they are required to cover Descovy specifically. If they cover Truvada and all associated labwork or outpatient visits without any out-of-pocket costs for you, that&#x27;s sufficient to comply with the law.<p>&gt; This doesn&#x27;t stop health insurance companies from trying to deny you, of course. You have to appeal the denial all the way up to your state&#x27;s department for health insurance, which you will definitely win.<p>Having helped many people who&#x27;ve been in this exact situation, it&#x27;s unfortunately not a given that you will win (you have to play your cards <i>exactly</i> right), and most people who need it can&#x27;t afford to pay over $2000&#x2F;month for the several months it takes for this to happen[0].<p>The most likely scenario is that the insurance company wins, because you give up.<p>[0] The insurance company has something like 30 days to respond for the first appeal, then an additional 45 for the second and third rounds, and that&#x27;s assuming everything happens on schedule and you respond to everything immediately.</div><br/><div id="41186065" class="c"><input type="checkbox" id="c-41186065" checked=""/><div class="controls bullet"><span class="by">argonaut</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185981">parent</a><span>|</span><a href="#41187271">next</a><span>|</span><label class="collapse" for="c-41186065">[-]</label><label class="expand" for="c-41186065">[1 more]</label></div><br/><div class="children"><div class="content">You are right, my comment is only valid in California.</div><br/></div></div><div id="41187271" class="c"><input type="checkbox" id="c-41187271" checked=""/><div class="controls bullet"><span class="by">FireBeyond</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185981">parent</a><span>|</span><a href="#41186065">prev</a><span>|</span><a href="#41185864">next</a><span>|</span><label class="collapse" for="c-41187271">[-]</label><label class="expand" for="c-41187271">[1 more]</label></div><br/><div class="children"><div class="content">There is also an emerging market for companies that will help you fight health insurers, and I&#x27;d have to imagine that they have some playbooks or can develop them for common situations.<p>And if not, maybe there should be. I saw some ugly shit in my days working for a company that wrote software for some of the bigger insurers.<p>Hmm.</div><br/></div></div></div></div></div></div><div id="41185864" class="c"><input type="checkbox" id="c-41185864" checked=""/><div class="controls bullet"><span class="by">chimeracoder</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185591">parent</a><span>|</span><a href="#41185913">prev</a><span>|</span><a href="#41185580">next</a><span>|</span><label class="collapse" for="c-41185864">[-]</label><label class="expand" for="c-41185864">[1 more]</label></div><br/><div class="children"><div class="content">&gt; The problem I think really comes down to there being a generic Truvada.<p>Truvada has been generic for about six years now.<p>&gt; I recently switched insurance companies and my new one covers Truvada completely, not even a copay. Itâs honestly kinda wild I pay more for my Adderall than I do prep.<p>That&#x27;s because under the ACA, insurance companies are legally required to cover PrEP at no out-of-pocket cost, without any cost-sharing, copays, or deductibles applied. This also applies to associated labwork and outpatient office visits.<p>Unfortunately, many insurance companies ignore this requirement, and it&#x27;s very difficult as an individual to get them to comply.</div><br/></div></div></div></div><div id="41185580" class="c"><input type="checkbox" id="c-41185580" checked=""/><div class="controls bullet"><span class="by">borski</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185427">parent</a><span>|</span><a href="#41185591">prev</a><span>|</span><a href="#41185381">next</a><span>|</span><label class="collapse" for="c-41185580">[-]</label><label class="expand" for="c-41185580">[3 more]</label></div><br/><div class="children"><div class="content">Iâm confused. The parent comment said âlonger term,â and you went on to discuss how it is not going to be used in the short term, due to the need for more testing and cost.<p>Cost comes down over time, and more testing occurs over time, somewhat by definition.<p>Soâ¦ what specifically is debatable about the longer term?</div><br/><div id="41185909" class="c"><input type="checkbox" id="c-41185909" checked=""/><div class="controls bullet"><span class="by">chimeracoder</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185580">parent</a><span>|</span><a href="#41185381">next</a><span>|</span><label class="collapse" for="c-41185909">[-]</label><label class="expand" for="c-41185909">[2 more]</label></div><br/><div class="children"><div class="content">&gt; Cost comes down over time, and more testing occurs over time, somewhat by definition.<p>Truvada has been around for over twenty years, and generic for 4-5 years. It still costs $2000&#x2F;month list price.<p>More testing doesn&#x27;t just magically happen either. Gilead has chosen for years not to pursue testing, let alone approval, for Descovy in various groups excluded from the original clinical trials. They&#x27;ve decided it&#x27;s not profitable enough for them. The same could very easily happen with lencapavir, and in fact there&#x27;s good reason to suspect it will.</div><br/><div id="41185966" class="c"><input type="checkbox" id="c-41185966" checked=""/><div class="controls bullet"><span class="by">borski</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185909">parent</a><span>|</span><a href="#41185381">next</a><span>|</span><label class="collapse" for="c-41185966">[-]</label><label class="expand" for="c-41185966">[1 more]</label></div><br/><div class="children"><div class="content">Why is it so expensive? And is it covered by insurance? If so, then I&#x27;m not sure the list price matters all that much from a &#x27;to most people&#x27; perspective, even if there is a moral argument to be had here (in which we&#x27;d probably agree).<p>I&#x27;m not entirely sure what the argument is, though - is it just the cynical argument of &quot;well, these companies don&#x27;t care about solving problems, just profit, so they&#x27;re never going to do anything with it&quot;? If so, then at least I understand your argument, even if I don&#x27;t necessarily agree.<p>But I tend to be an optimist.</div><br/></div></div></div></div></div></div></div></div></div></div><div id="41185381" class="c"><input type="checkbox" id="c-41185381" checked=""/><div class="controls bullet"><span class="by">masspro</span><span>|</span><a href="#41184899">parent</a><span>|</span><a href="#41184919">prev</a><span>|</span><a href="#41185210">next</a><span>|</span><label class="collapse" for="c-41185381">[-]</label><label class="expand" for="c-41185381">[2 more]</label></div><br/><div class="children"><div class="content">PEP means &quot;post-exposure prophylaxis&quot;; PrEP means &quot;pre-exposure prophylaxis&quot;. You take PrEP regularly (if you know you&#x27;re at risk due to sexual habits etc whatever), but only take PEP in response to a specific possible-exposure event (and not already on PrEP). You want pre-exposure instead of post-exposure because post-exposure is very hard on your body and makes you feel sick.</div><br/><div id="41186639" class="c"><input type="checkbox" id="c-41186639" checked=""/><div class="controls bullet"><span class="by">dyauspitr</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185381">parent</a><span>|</span><a href="#41185210">next</a><span>|</span><label class="collapse" for="c-41186639">[-]</label><label class="expand" for="c-41186639">[1 more]</label></div><br/><div class="children"><div class="content">Why is post exposure so hard on the body. Isnât it still just a 2 drug cocktail (truvada+another one)?</div><br/></div></div></div></div><div id="41185210" class="c"><input type="checkbox" id="c-41185210" checked=""/><div class="controls bullet"><span class="by">4fterd4rk</span><span>|</span><a href="#41184899">parent</a><span>|</span><a href="#41185381">prev</a><span>|</span><a href="#41184946">next</a><span>|</span><label class="collapse" for="c-41185210">[-]</label><label class="expand" for="c-41185210">[6 more]</label></div><br/><div class="children"><div class="content">PrEP - An HIV negative person taking Truvada or Descovy once a day to prevent HIV infection.<p>PEP - An HIV negative person taking a course of antiretrovirals within 72 hours after exposure to HIV to prevent HIV infection.<p>This article is referring to injectable PrEP. This is already available via an injection every two months and is typically used in populations that can&#x27;t be expected to take a pill every day (drug addicts, etc.). The article is referring to a new form of injectable PrEP that extends this to once every six months.</div><br/><div id="41185484" class="c"><input type="checkbox" id="c-41185484" checked=""/><div class="controls bullet"><span class="by">chimeracoder</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185210">parent</a><span>|</span><a href="#41184946">next</a><span>|</span><label class="collapse" for="c-41185484">[-]</label><label class="expand" for="c-41185484">[5 more]</label></div><br/><div class="children"><div class="content">&gt; This is already available via an injection every two months and is typically used in populations that can&#x27;t be expected to take a pill every day (drug addicts, etc.).<p>That is a pretty bold parenthetical statement. Not only is it <i>not</i> true that &quot;drug addicts&quot; can&#x27;t be expected to take a pill every day, but neither cabotegravir nor lenacapavir are tested or approved for HIV acquired through non-sexual means, which makes them a poor choice for PrEP for &quot;drug addicts&quot; compared to oral forms, which <i>are</i> effective against all forms of HIV transmission.<p>Source: former counselor and educator for HIV and substance use</div><br/><div id="41185528" class="c"><input type="checkbox" id="c-41185528" checked=""/><div class="controls bullet"><span class="by">fragmede</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185484">parent</a><span>|</span><a href="#41184946">next</a><span>|</span><label class="collapse" for="c-41185528">[-]</label><label class="expand" for="c-41185528">[4 more]</label></div><br/><div class="children"><div class="content">&gt; Not only is it not true that &quot;drug addicts&quot; can&#x27;t be expected to take a pill every day,<p>The general population can&#x27;t be expected to take a pill every day, what would make anyone believe people with SUD are able to?<p>Source: person who&#x27;s expected to take a pill every day, and knows other people who are supposed to taste a pill every day.</div><br/><div id="41185940" class="c"><input type="checkbox" id="c-41185940" checked=""/><div class="controls bullet"><span class="by">chimeracoder</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185528">parent</a><span>|</span><a href="#41184946">next</a><span>|</span><label class="collapse" for="c-41185940">[-]</label><label class="expand" for="c-41185940">[3 more]</label></div><br/><div class="children"><div class="content">&gt; The general population can&#x27;t be expected to take a pill every day, what would make anyone believe people with SUD are able to?<p>The general population <i>does</i> take PrEP regularly enough to be protected. You seem think that people with substance use disorders are excluded from that, and that belief is grounded in stereotype and bias, not science.<p>Source: clinical data and professional experience</div><br/><div id="41188406" class="c"><input type="checkbox" id="c-41188406" checked=""/><div class="controls bullet"><span class="by">curiousthought</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41185940">parent</a><span>|</span><a href="#41184946">next</a><span>|</span><label class="collapse" for="c-41188406">[-]</label><label class="expand" for="c-41188406">[2 more]</label></div><br/><div class="children"><div class="content">Adherence to a single tablet regimen is significantly higher than a multi tablet regimen. Bringing some actual data into this, adherence to either in a broad population is not 100%: 
<a href="https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC5253105&#x2F;#:~:text=Adherence%20greater%20than%20or%20equal,%2Ddose%20MTR%20(66%25)" rel="nofollow">https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC5253105&#x2F;#:~:tex...</a>.<p>People with substance abuse disorders are not binarily excluded or included from adherence to taking a daily regimen. However, it is not an unreasonable expectation that someone shooting heroin every week in a flop house is less likely to take a daily medicine than the average population.<p>The belief that drug addicts can&#x27;t be expected to take a daily pill is not grounded in stereotype and bias, it&#x27;s a realistic and down to earth perspective that for some of them, their addiction is crippling their ability to function.</div><br/></div></div></div></div></div></div></div></div></div></div><div id="41184946" class="c"><input type="checkbox" id="c-41184946" checked=""/><div class="controls bullet"><span class="by">nerdjon</span><span>|</span><a href="#41184899">parent</a><span>|</span><a href="#41185210">prev</a><span>|</span><a href="#41184981">next</a><span>|</span><label class="collapse" for="c-41184946">[-]</label><label class="expand" for="c-41184946">[5 more]</label></div><br/><div class="children"><div class="content">What I have noticed is that in most situations saying &quot;PrEP&quot; is enough. For my doctor that meant discussing Truvada, Descovy, and what is just kinda dubbed &quot;Injectable Prep&quot;.  This aligns with most apps also just saying &quot;on prep&quot; with no distinguishing between what prep.<p>I would imagine that if&#x2F;when this comes to market it would likely similarly fall under &quot;Prep&quot; for the general community and then you discuss the specifics with your doctor.<p>Edit: There is also Doxypep (I just say Doxy), which while related to STD&#x27;s is not related to HIV.</div><br/><div id="41186390" class="c"><input type="checkbox" id="c-41186390" checked=""/><div class="controls bullet"><span class="by">felixg3</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41184946">parent</a><span>|</span><a href="#41184981">next</a><span>|</span><label class="collapse" for="c-41186390">[-]</label><label class="expand" for="c-41186390">[4 more]</label></div><br/><div class="children"><div class="content">There are people announcing their PrEP status on dating apps so they can raw dog with strangers? Have people forgotten that there are plenty of STD besides HIV?
I think this is highly problematic and lifestyle PrEP seems to be counterproductive as a public health measure.<p>But I am open to arguments that Iâm wrong. Itâs possible that I am biased as a monogamous heterosexual who has grown up in a culture where sex without condom, especially outside committed relationships, is generally frowned upon and 1980-1990s HIV scares are still in the consciousness of people.</div><br/><div id="41186574" class="c"><input type="checkbox" id="c-41186574" checked=""/><div class="controls bullet"><span class="by">iknowstuff</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41186390">parent</a><span>|</span><a href="#41184981">next</a><span>|</span><label class="collapse" for="c-41186574">[-]</label><label class="expand" for="c-41186574">[3 more]</label></div><br/><div class="children"><div class="content">Nobodyâs giving or getting head with a condom. People who stay on top of preventative measures tend to not bother with condoms since PrEP became prevalent, because the rest of them you can get with or without a condom due to oral.<p>Preventative:<p>1. Gardasil 9 (vaccine against 9 strains of HPV, prevents genital warts and cancers caused by HPV)<p>2. Monkeypox vaccine<p>3. Meningitis ACYW vax<p>4. Meningitis B vax (35% effective against gonorrhea)<p>5. doxyPEP (two pills of doxycycline taken after sex, 90% effective against syphilis, 80% chlamydia, 50% gonorrhea)<p>6. PrEP (prevents HIV infections)<p>7. and the usual suite of vaccines against the rest like hepatitis A&#x2F;B, mumps etc<p>Youâll notice all of these give you far more protection than a condom would. Again, especially since oral is a thing.<p>Treatment of the bacterial ones (which transmit through oral too):<p>1. syphilis - butt shot of penicillin<p>2. chlamydia - 1&#x2F;2 pills of an antibiotic<p>3. gonorrhea - a week of doxycycline pills or one butt shot of ceftriaxone<p>Remaining unpreventable&#x2F;untreatable one is HSV. Half of the population has it. Condoms dont prevent it either.<p>Hepatitis requires blood contact and as such is not necessarily considered an STI, but hepatitis c is curable these days thanks to DAAs taken over the course of 8-12 weeks, and a&#x2F;b variants have vaccines.</div><br/><div id="41187312" class="c"><input type="checkbox" id="c-41187312" checked=""/><div class="controls bullet"><span class="by">theideaofcoffee</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41186574">parent</a><span>|</span><a href="#41187411">next</a><span>|</span><label class="collapse" for="c-41187312">[-]</label><label class="expand" for="c-41187312">[1 more]</label></div><br/><div class="children"><div class="content">Thank you for adding this here, I was working on compiling something similar for another comment on the thread. This is pretty much the gold standard and yeah those that keep up on preventatives and testing are usually the least likely to pass anything along. More information is better, not less! These puritanical views on human sexuality, like the comment above yours to which you&#x27;re responding and others, only cause more hurt and don&#x27;t really have any sort of deterrent effect. Peeps be fuckin&#x27;, nothing you can do to stop it besides get the best info and treatments out there.</div><br/></div></div><div id="41187411" class="c"><input type="checkbox" id="c-41187411" checked=""/><div class="controls bullet"><span class="by">scotty79</span><span>|</span><a href="#41184899">root</a><span>|</span><a href="#41186574">parent</a><span>|</span><a href="#41187312">prev</a><span>|</span><a href="#41184981">next</a><span>|</span><label class="collapse" for="c-41187411">[-]</label><label class="expand" for="c-41187411">[1 more]</label></div><br/><div class="children"><div class="content">Great list. Although suddenly sex when single seems like even more of a bother than before.</div><br/></div></div></div></div></div></div></div></div></div></div><div id="41186005" class="c"><input type="checkbox" id="c-41186005" checked=""/><div class="controls bullet"><span class="by">nothrowaways</span><span>|</span><a href="#41184899">prev</a><span>|</span><a href="#41188020">next</a><span>|</span><label class="collapse" for="c-41186005">[-]</label><label class="expand" for="c-41186005">[7 more]</label></div><br/><div class="children"><div class="content">&gt; The medication interrupts viral replication by preventing HIV from reaching the nucleus of an infected cell.<p>How does it actually do it?</div><br/><div id="41186094" class="c"><input type="checkbox" id="c-41186094" checked=""/><div class="controls bullet"><span class="by">tjohns</span><span>|</span><a href="#41186005">parent</a><span>|</span><a href="#41186080">next</a><span>|</span><label class="collapse" for="c-41186094">[-]</label><label class="expand" for="c-41186094">[4 more]</label></div><br/><div class="children"><div class="content">From Wikipedia:<p>&quot;Lenacapavir works by binding directly to the interface between HIV-1 viral capsid protein (p24) subunits in capsid hexamers, interfering with essential steps of viral replication, including capsid-mediated nuclear uptake of HIV-1 proviral DNA, virus assembly and release, production of capsid protein subunits, and capsid core formation[1]... It functions by binding to the hydrophobic pocket formed by two neighboring protein subunits in the capsid shell. This bond stabilizes the capsid structure and inhibits the functional disassembly of the capsid in infected cells.[2]&quot;<p>In other words, it prevents the virus&#x27; protein shell (capsid) from being built properly, which in turn prevents the virus from properly opening (&quot;uncoating&quot;) once it enters a host cell.<p>[1]: <a href="https:&#x2F;&#x2F;en.wikipedia.org&#x2F;wiki&#x2F;Lenacapavir" rel="nofollow">https:&#x2F;&#x2F;en.wikipedia.org&#x2F;wiki&#x2F;Lenacapavir</a><p>[2]: <a href="https:&#x2F;&#x2F;en.wikipedia.org&#x2F;wiki&#x2F;HIV_capsid_inhibition" rel="nofollow">https:&#x2F;&#x2F;en.wikipedia.org&#x2F;wiki&#x2F;HIV_capsid_inhibition</a></div><br/><div id="41186912" class="c"><input type="checkbox" id="c-41186912" checked=""/><div class="controls bullet"><span class="by">akira2501</span><span>|</span><a href="#41186005">root</a><span>|</span><a href="#41186094">parent</a><span>|</span><a href="#41186668">next</a><span>|</span><label class="collapse" for="c-41186912">[-]</label><label class="expand" for="c-41186912">[1 more]</label></div><br/><div class="children"><div class="content">&gt; It functions by binding to the hydrophobic pocket formed by two neighboring protein subunits in the capsid shell<p>That&#x27;s entirely cool to me,  it operates by exploiting an &quot;incidental construction feature&quot; of the capsid and not targeting any specific feature in and of itself?</div><br/></div></div><div id="41186668" class="c"><input type="checkbox" id="c-41186668" checked=""/><div class="controls bullet"><span class="by">nothrowaways</span><span>|</span><a href="#41186005">root</a><span>|</span><a href="#41186094">parent</a><span>|</span><a href="#41186912">prev</a><span>|</span><a href="#41186080">next</a><span>|</span><label class="collapse" for="c-41186668">[-]</label><label class="expand" for="c-41186668">[2 more]</label></div><br/><div class="children"><div class="content">Thought Lenacapavir was just a chemical. If it knows where the nucleus is, is Lenacapavir an organism?</div><br/><div id="41186800" class="c"><input type="checkbox" id="c-41186800" checked=""/><div class="controls bullet"><span class="by">tjohns</span><span>|</span><a href="#41186005">root</a><span>|</span><a href="#41186668">parent</a><span>|</span><a href="#41186080">next</a><span>|</span><label class="collapse" for="c-41186800">[-]</label><label class="expand" for="c-41186800">[1 more]</label></div><br/><div class="children"><div class="content">Yes, Lenacapavir is just a chemical.<p>It&#x27;s HIV itself that &quot;knows&quot; where the nucleus is and is actively trying to get there once it&#x27;s inside your cell. It does this by walking itself along your cell&#x27;s microtubial network. It would be fascinating if it wasn&#x27;t so deadly.<p>I&#x27;d recommend watching this video: <a href="https:&#x2F;&#x2F;vimeo.com&#x2F;260291607" rel="nofollow">https:&#x2F;&#x2F;vimeo.com&#x2F;260291607</a><p>See timestamps 1:33 and 2:47.</div><br/></div></div></div></div></div></div><div id="41186080" class="c"><input type="checkbox" id="c-41186080" checked=""/><div class="controls bullet"><span class="by">mrtesthah</span><span>|</span><a href="#41186005">parent</a><span>|</span><a href="#41186094">prev</a><span>|</span><a href="#41188020">next</a><span>|</span><label class="collapse" for="c-41186080">[-]</label><label class="expand" for="c-41186080">[2 more]</label></div><br/><div class="children"><div class="content">by preventing viral capsid assembly, as noted in the article.<p>Once bound to the P24 capsid protein, the drug also interferes with other stages of the virusâ lifecycle[1]:<p>&gt;<i>Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid protein (p24) subunits in hexamers. Surface plasmon resonance sensorgrams showed dose-dependent and saturable binding of lenacapavir to cross-linked wild-type capsid hexamer with an equilibrium binding constant (KD) of 1.4 nM. Lenacapavir inhibits HIV-1 replication by interfering with multiple essential steps of the viral lifecycle, including capsid-mediated nuclear uptake of HIV-1 proviral DNA (by blocking nuclear import proteins binding to capsid), virus assembly and release (by interfering with Gag&#x2F;Gag-Pol functioning, reducing production of capsid protein subunits), and capsid core formation (by disrupting the rate of capsid subunit association, leading to malformed capsids).</i><p>1. <a href="https:&#x2F;&#x2F;dailymed.nlm.nih.gov&#x2F;dailymed&#x2F;drugInfo.cfm?setid=e5652804-29c4-40d7-aeb2-0142ed2a7b5b#S12.4" rel="nofollow">https:&#x2F;&#x2F;dailymed.nlm.nih.gov&#x2F;dailymed&#x2F;drugInfo.cfm?setid=e56...</a></div><br/></div></div></div></div><div id="41188020" class="c"><input type="checkbox" id="c-41188020" checked=""/><div class="controls bullet"><span class="by">wsc981</span><span>|</span><a href="#41186005">prev</a><span>|</span><a href="#41187977">next</a><span>|</span><label class="collapse" for="c-41188020">[-]</label><label class="expand" for="c-41188020">[2 more]</label></div><br/><div class="children"><div class="content">With regards to HIV and Aids, Nobel price winner Kary Mullis (inventor of PCR test), made many interesting remarks. I thought that was an interesting interview.<p><a href="https:&#x2F;&#x2F;www.youtube.com&#x2F;watch?v=W1FXbxDrDrY" rel="nofollow">https:&#x2F;&#x2F;www.youtube.com&#x2F;watch?v=W1FXbxDrDrY</a><p>It&#x27;s a quite old interview (1996), wonder in what ways knowledge has changed regarding the disease.</div><br/><div id="41188501" class="c"><input type="checkbox" id="c-41188501" checked=""/><div class="controls bullet"><span class="by">mercutio2</span><span>|</span><a href="#41188020">parent</a><span>|</span><a href="#41187977">next</a><span>|</span><label class="collapse" for="c-41188501">[-]</label><label class="expand" for="c-41188501">[1 more]</label></div><br/><div class="children"><div class="content">Kary Mullisâs AIDS denial has been very, very thoroughly debunked.<p>I would not recommend listening to him about AIDS.</div><br/></div></div></div></div><div id="41187977" class="c"><input type="checkbox" id="c-41187977" checked=""/><div class="controls bullet"><span class="by">iEchoic</span><span>|</span><a href="#41188020">prev</a><span>|</span><a href="#41186908">next</a><span>|</span><label class="collapse" for="c-41187977">[-]</label><label class="expand" for="c-41187977">[1 more]</label></div><br/><div class="children"><div class="content">Derek Lowe is a great writer. Worth reading his &quot;Things I Won&#x27;t Work With&quot; articles if you want to read more of his writing.<p><a href="https:&#x2F;&#x2F;www.science.org&#x2F;content&#x2F;blog-post&#x2F;things-i-won-t-work-dioxygen-difluoride" rel="nofollow">https:&#x2F;&#x2F;www.science.org&#x2F;content&#x2F;blog-post&#x2F;things-i-won-t-wor...</a></div><br/></div></div><div id="41186908" class="c"><input type="checkbox" id="c-41186908" checked=""/><div class="controls bullet"><span class="by">happybuy</span><span>|</span><a href="#41187977">prev</a><span>|</span><a href="#41185559">next</a><span>|</span><label class="collapse" for="c-41186908">[-]</label><label class="expand" for="c-41186908">[5 more]</label></div><br/><div class="children"><div class="content">As with all drugs, efficacy is only one part of the equation.<p>What&#x27;s the potential side effects, both short term and long term, of this treatment?<p>For this treatment, it may be negligible, but without saying so we are only hearing one side of the story.</div><br/><div id="41187025" class="c"><input type="checkbox" id="c-41187025" checked=""/><div class="controls bullet"><span class="by">hyrix</span><span>|</span><a href="#41186908">parent</a><span>|</span><a href="#41185559">next</a><span>|</span><label class="collapse" for="c-41187025">[-]</label><label class="expand" for="c-41187025">[4 more]</label></div><br/><div class="children"><div class="content">They stopped the study because of the incredible efficacy and lack of side effects. This was a phase 3 clinical trial so they have already cleared substantial hurdles in safety requirements (clinical trials are about both efficacy and side effects).<p>But for argumentâs sake, there are even more sides than efficacy and safety: there are substantially different risk profiles for different potential patients, and a long acting treatment with no daily pill is more valuable for some people.<p>One of the reasons that long acting injectables could have a big impact on transmission in Africa is because thereâs stigma around PrEP usage, especially for women. Obviously, there is now a big conversation about the cost and who pays, but the potential here is indisputable.<p><a href="https:&#x2F;&#x2F;www.niaid.nih.gov&#x2F;news-events&#x2F;nih-statement-preliminary-efficacy-results-twice-yearly-lenacapavir-hiv-prevention" rel="nofollow">https:&#x2F;&#x2F;www.niaid.nih.gov&#x2F;news-events&#x2F;nih-statement-prelimin...</a><p><a href="https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC10879468&#x2F;" rel="nofollow">https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC10879468&#x2F;</a></div><br/><div id="41187366" class="c"><input type="checkbox" id="c-41187366" checked=""/><div class="controls bullet"><span class="by">breck</span><span>|</span><a href="#41186908">root</a><span>|</span><a href="#41187025">parent</a><span>|</span><a href="#41185559">next</a><span>|</span><label class="collapse" for="c-41187366">[-]</label><label class="expand" for="c-41187366">[3 more]</label></div><br/><div class="children"><div class="content">&gt; They stopped the study because of the incredible efficacy and lack of side effects.<p>Are you aware that historically when this has happened, it almost always turns out to have negative side effects and marginal efficacy?<p>Don&#x27;t you think an easy con is to flip a coin 3 times, and if you get heads all 3 times, tell everyone it always comes up heads, and there&#x27;s no need to continue to measure it, but just to trust them?</div><br/><div id="41188379" class="c"><input type="checkbox" id="c-41188379" checked=""/><div class="controls bullet"><span class="by">hyrix</span><span>|</span><a href="#41186908">root</a><span>|</span><a href="#41187366">parent</a><span>|</span><a href="#41188392">next</a><span>|</span><label class="collapse" for="c-41188379">[-]</label><label class="expand" for="c-41188379">[1 more]</label></div><br/><div class="children"><div class="content">Usually when a study is halted early itâs because of obvious harm to the experimental group from the treatment which means there would be no possible benefit and it would make continuation unethical.<p>A meta analysis of early stopping in randomized clinical trials has found no evidence that early stopping hides side effects or inflates benefitâand I challenge you to produce any examples of a phase 3 trial of an infectious disease treatment that was stopped early which later showed unduly harmful side effects for marginal benefit.<p>This trial showed <i>100%</i> efficacy.<p>A major consideration of RCTs is also the benefit denied to the public by withholding a viable treatment. HIV remains a global epidemic with no existing good solutions for poor countries.<p><a href="https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC5133138&#x2F;" rel="nofollow">https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC5133138&#x2F;</a></div><br/></div></div><div id="41188392" class="c"><input type="checkbox" id="c-41188392" checked=""/><div class="controls bullet"><span class="by">dyauspitr</span><span>|</span><a href="#41186908">root</a><span>|</span><a href="#41187366">parent</a><span>|</span><a href="#41188379">prev</a><span>|</span><a href="#41185559">next</a><span>|</span><label class="collapse" for="c-41188392">[-]</label><label class="expand" for="c-41188392">[1 more]</label></div><br/><div class="children"><div class="content">I donât think anything is going to be as devastating as 60%+ of Eswatiniâs women between the ages of 25-39 being HIV+. Anything that can put a dent in that is going to far outweigh any potential risks and side effects. That whole country is going to be dead in 5-10 years unless they all get a daily dose of ART for the rest of their lives.<p>On a side note, that number is absolutely unbelievable considering that heterosexual intercourse has a 0.08% chance of infection. Do they all have 100s of sexual partners and tens of thousands of sexual interactions before theyâre 30?</div><br/></div></div></div></div></div></div></div></div><div id="41185559" class="c"><input type="checkbox" id="c-41185559" checked=""/><div class="controls bullet"><span class="by">w10-1</span><span>|</span><a href="#41186908">prev</a><span>|</span><a href="#41186056">next</a><span>|</span><label class="collapse" for="c-41185559">[-]</label><label class="expand" for="c-41185559">[5 more]</label></div><br/><div class="children"><div class="content">This is an historic achievement with huge benefits, particularly for Africa.<p>AFAIK, Gilead hasn&#x27;t detailed any commitment to making it available to all who need it.  There&#x27;s been talk of $4K -$42K yearly price. Gilead just this month is promising regulatory submissions for approvals soon.  The drugs sounds quite complicated and hence difficult to manufacture, perhaps making it an enduring franchise.<p>The original post is raising a most interesting question: in a world where preventing infection is possible, what&#x27;s the standard or incentive for a vaccine?  It&#x27;s rare to get 100% prevention from a vaccine.  The incentive would seem to depend only on cost, and any vaccine developer would know that Gilead can likely lower cost at will, making it impossible to recoup vaccine development costs.</div><br/><div id="41185851" class="c"><input type="checkbox" id="c-41185851" checked=""/><div class="controls bullet"><span class="by">DoreenMichele</span><span>|</span><a href="#41185559">parent</a><span>|</span><a href="#41185821">next</a><span>|</span><label class="collapse" for="c-41185851">[-]</label><label class="expand" for="c-41185851">[1 more]</label></div><br/><div class="children"><div class="content">A lot of health care problems are undermined by the profit motive angle.<p>I don&#x27;t know how to solve that because there&#x27;s no such thing as a free lunch and the people developing solutions deserve to be paid.<p>But Africa is extremely poor and the rest of the world suffers the consequences when we can&#x27;t be arsed to make their problems solvable at a price point they can afford.</div><br/></div></div><div id="41185821" class="c"><input type="checkbox" id="c-41185821" checked=""/><div class="controls bullet"><span class="by">KoolKat23</span><span>|</span><a href="#41185559">parent</a><span>|</span><a href="#41185851">prev</a><span>|</span><a href="#41185619">next</a><span>|</span><label class="collapse" for="c-41185821">[-]</label><label class="expand" for="c-41185821">[2 more]</label></div><br/><div class="children"><div class="content">It will be virtually non-existent in Africa if it is priced like that.</div><br/><div id="41186660" class="c"><input type="checkbox" id="c-41186660" checked=""/><div class="controls bullet"><span class="by">dyauspitr</span><span>|</span><a href="#41185559">root</a><span>|</span><a href="#41185821">parent</a><span>|</span><a href="#41185619">next</a><span>|</span><label class="collapse" for="c-41186660">[-]</label><label class="expand" for="c-41186660">[1 more]</label></div><br/><div class="children"><div class="content">It will be non existent in Africa until India starts making the generics. Thatâs how it has historically been for most prescription medication there.</div><br/></div></div></div></div><div id="41185619" class="c"><input type="checkbox" id="c-41185619" checked=""/><div class="controls bullet"><span class="by">ReptileMan</span><span>|</span><a href="#41185559">parent</a><span>|</span><a href="#41185821">prev</a><span>|</span><a href="#41186056">next</a><span>|</span><label class="collapse" for="c-41185619">[-]</label><label class="expand" for="c-41185619">[1 more]</label></div><br/><div class="children"><div class="content">&gt;The incentive would seem to depend only on cost, and any vaccine developer would know that Gilead can likely lower cost at will, making it impossible to recoup vaccine development costs.<p>This is a good argument that some drugs should be developed by state grants or bounties and the patent is in the state. Something similar delivered covid vaccines in record time - in the form of massive pre purchase agreements.</div><br/></div></div></div></div><div id="41186056" class="c"><input type="checkbox" id="c-41186056" checked=""/><div class="controls bullet"><span class="by">nothrowaways</span><span>|</span><a href="#41185559">prev</a><span>|</span><a href="#41186656">next</a><span>|</span><label class="collapse" for="c-41186056">[-]</label><label class="expand" for="c-41186056">[6 more]</label></div><br/><div class="children"><div class="content">&gt; Among 5338 participants who were initially HIV-negative, 55 incident HIV infections were observed...<p>Wait what? Those 55 got infected during the trial. What was the incentive to get exposed?</div><br/><div id="41188313" class="c"><input type="checkbox" id="c-41188313" checked=""/><div class="controls bullet"><span class="by">HaZeust</span><span>|</span><a href="#41186056">parent</a><span>|</span><a href="#41186180">next</a><span>|</span><label class="collapse" for="c-41188313">[-]</label><label class="expand" for="c-41188313">[1 more]</label></div><br/><div class="children"><div class="content">So I won&#x27;t tell you to keep reading like others (which you should), but these studies don&#x27;t work by some research scientist having an HIV+ blood IV at the ready with some &quot;you might notice a little prick&quot; trope, they offer these medications to people that are already in high-risk groups and are conducting activities that make them the most likely demographic to obtain or transmit HIV. Folks like promiscuous homosexuals, prostitutes, drug addicts (risk of sharing needles), and focus groups like that.</div><br/></div></div><div id="41186180" class="c"><input type="checkbox" id="c-41186180" checked=""/><div class="controls bullet"><span class="by">cypherpunks01</span><span>|</span><a href="#41186056">parent</a><span>|</span><a href="#41188313">prev</a><span>|</span><a href="#41189175">next</a><span>|</span><label class="collapse" for="c-41186180">[-]</label><label class="expand" for="c-41186180">[1 more]</label></div><br/><div class="children"><div class="content">Yes, it can be confusing if you only read part of a sentence. Recommend continue reading if you&#x27;re interested in the findings</div><br/></div></div><div id="41189175" class="c"><input type="checkbox" id="c-41189175" checked=""/><div class="controls bullet"><span class="by">sureIy</span><span>|</span><a href="#41186056">parent</a><span>|</span><a href="#41186180">prev</a><span>|</span><a href="#41186137">next</a><span>|</span><label class="collapse" for="c-41189175">[-]</label><label class="expand" for="c-41189175">[1 more]</label></div><br/><div class="children"><div class="content">HNers need to stop downvoting questions, however âstupidâ they might sound.</div><br/></div></div><div id="41186137" class="c"><input type="checkbox" id="c-41186137" checked=""/><div class="controls bullet"><span class="by">matthewmacleod</span><span>|</span><a href="#41186056">parent</a><span>|</span><a href="#41189175">prev</a><span>|</span><a href="#41186656">next</a><span>|</span><label class="collapse" for="c-41186137">[-]</label><label class="expand" for="c-41186137">[2 more]</label></div><br/><div class="children"><div class="content">All 55 of those infections were observed in trial participants randomised to the tenofovir&#x2F;emtracitabine groups. There were no infections in the lenacapavir group.</div><br/><div id="41186335" class="c"><input type="checkbox" id="c-41186335" checked=""/><div class="controls bullet"><span class="by">kemitche</span><span>|</span><a href="#41186056">root</a><span>|</span><a href="#41186137">parent</a><span>|</span><a href="#41186656">next</a><span>|</span><label class="collapse" for="c-41186335">[-]</label><label class="expand" for="c-41186335">[1 more]</label></div><br/><div class="children"><div class="content">The site also indicated that &quot;Adherence to F&#x2F;TAF and F&#x2F;TDF was low&quot; which means those that got infected most likely weren&#x27;t taking their pills on a daily basis, unfortunately.</div><br/></div></div></div></div></div></div><div id="41186656" class="c"><input type="checkbox" id="c-41186656" checked=""/><div class="controls bullet"><span class="by">jaymee</span><span>|</span><a href="#41186056">prev</a><span>|</span><a href="#41189404">next</a><span>|</span><label class="collapse" for="c-41186656">[-]</label><label class="expand" for="c-41186656">[1 more]</label></div><br/><div class="children"><div class="content">I hope that vaccines can be made affordable, otherwise, it won&#x27;t solve anything.</div><br/></div></div></div></div></div></div></div></body></html>